Home Ricerca Sedi Chi siamo Organigramma Personale Contatti Didattica Login Documenti EN
Progetti in evidenza
INCIPIT
(Link esterno)

ISTAPCA
(1209 visite)

Fondo Europeo Pesca
(622 visite)

Euro-BioImaging
(Link esterno)

Fondazione Veronesi
(Link esterno)

LightDyNAmics
(1094 visite)

 INMiND
(1186 visite)

Instruct-IT
(Link esterno)

 PRIN
(1329 visite)

 eHealthNet
(1090 visite)

Ponrec
(1028 visite)

MFAG Grant
(1134 visite)

MERIT
(Link esterno)


Collegamenti

Contiene: [X]      Estesa     Autori: [X]  Tipo di lavoro: [X]   Data iniziale: Data finale: [X]      Sede: Affiliazione IBB     
    
[Pulisci modulo]


Peptides for tumour therapy and diagnosis: current status and future directions (216 visite)

Zaccaro L, Del Gatto A, Pedone C, Saviano M

Curr Med Chem (ISSN: 0929-8673, 1875-533x, 1875-533xelectronic), 2009 Mar; 16(7): 780-795.



Tipo di articolo: Journal Article, Research Support, Non-U. S. Gov'T, Review,

Impact factor: 4.708, Impact factor a 5 anni: 5.387

Url: http://www.scopus.com/inward/record.url?eid=2-s2.0-65649117755&partnerID=40&md5=cdd96a1100d9d9938e34dcf08a217bfa

Parole chiave: Cck, Integrin, Somatostatin, Structure-Activity Relationships, Tumour Diseases, 4 [[5 (8 Azaspiro[4.5]decan 8 Yl) 4 [(3, 5 Dichlorobenzoyl)amino] 5 Oxopentanoyl]amino] 5 (1 Naphthylamino) 5 Oxopentanoic Acid, Angiopeptin, Arginylglycylaspartic Acid, Cholecystokinin, Cholecystokinin Receptor, Cholecystokinin Receptor Blocking Agent, Cilengitide, Cr 2345, Cr 2767, Depreotide Tc 99m, Integrin Receptor, Itriglumide, Lorglumide, Loxiglumide, Nc 100692 Technetium Tc 99m, Octreotate[3 Tyrosine 1, 10 Tetraazacyclododecane 1, 10 Tetraacetic Acid Lu 177], Octreotide, Octreotide[3 Tyrosine 1, 10 Tetraacetic Acid Y 90], Pasireotide, Pentetreotide In 111, Proglumide, Radiopharmaceutical Agent, Somatostatin Derivative, Somatostatin Receptor, Spiroglumide, Unclassified Drug, Unindexed Drug, Vapreotide, Acromegaly, Antiangiogenic Activity, Breast Cancer, Cancer Chemotherapy, Cancer Diagnosis, Cancer Scintiscanning, Carcinoid, Clinical Trial, Diagnostic Accuracy, Drug Distribution, Drug Megadose, Drug Metabolism, Drug Receptor Binding, Drug Structure, Drug Synthesis, Gastrinoma, Gastrointestinal Tumor, Human, Isotope Labeling, Liver Metastasis, Neuroendocrine Tumor, Nonhuman, Paraganglioma, Protein Expression, Protein Targeting, Review, Single Photon Emission Computer Tomography, Thyroid Medullary Carcinoma, Amino Acid Sequence, Animals, Drug Delivery Systems, Molecular Sequence Data, Neoplasms, Peptides, 4 [[5 (8 Azaspiro [4. 5] Decan 8 Yl) 4 [(3, 5 Dichlorobenzoyl) Amino] 5 Oxopentanoyl] Amino] 5 (1 Naphthylamino) 5 Oxopentanoic Acid, Octreotate [3 Tyrosine 1, Octreotide [3 Tyrosine 1,

Affiliazioni:

*** IBB - CNR ***
Department of Biological Sciences, University of Naples Federico II, via Mezzocannone 16, 80134, Napoli, Italy.
Institute of Biostructures and Bioimaging, CNR, University of Naples Federico II, via Mezzocannone 16, 80134 Napoli, Italy



Riferimenti:

Okarvi, S.M., Peptide-based radiopharmaceuticals: Future tools for diagnostic imaging of cancers and other diseases (2004) Med. Res. Rev, 24, pp. 357-39

Biron, E., Chatterjee, J., Ovadia, O., Langenegger, D., Brueggen, J., Hoyer, D., Schmid, H.A., Kessler, H., Improving oral bioavailability of peptides by multiple N-methylation: Somatostatin analogues (2008) Angew. Chem. Int. Ed. Eng, 47, pp. 2595-2599

Patel, Y.C., Somatostatin and its receptor family (1999) Front. Neuroendocrinol, 20, pp. 157-198

Lewin, M.J., The somatostatin receptor in the GI tract (1992) Annu. Rev. Physiol, 54, pp. 455-468

Bousquet, C., Puente, E., Buscail, L., Vaysse, N., Susini, C., Antiproliferative effect of somatostatin and analogs (2001) Chemotherapy, 47 (SUPPL. 2), pp. 30-39

Hu, C., Yi, C., Hao, Z., Cao, S., Li, H., Shao, X., Zhang, J., Fan, D., (2004) Cancer Biol. Ther, 3, pp. 726-730

Bruno, J.F., Xu, Y., Song, J., Berelowitz, M., Molecular cloning and functional expression of a brain-specific somatostatin receptor (1992) Proc. Natl. Acad. Sci. USA, 89, pp. 11151-11155

Meyerhof, W., The elucidation of somatostatin receptor functions: A current view (1998) Rev. Physiol. Biochem. Pharmacol, 133, pp. 55-108

Reisine, T., Bell, G.I., Molecular biology of somatostatin receptors (1995) Endocr. Rev, 16, pp. 427-442

Vanetti, M., Kouba, M., Wang, X., Vogt, G., Hollt, V., Cloning and expression of a novel mouse somatostatin receptor (SSTR2B) (1992) FEBS Lett, 311, pp. 290-294

Vanetti, M., Vogt, G., Hollt, V., The two isoforms of the mouse somatostatin receptor (mSSTR2A and mSSTR2B) differ in coupling efficiency to adenylate cyclase and in agonist-induced receptor desensitization (1993) FEBS Lett, 331, pp. 260-266

Rocheville, M., Lange, D.C., Kumar, U., Sasi, R., Patel, R.C., Patel, Y.C., Subtypes of the somatostatin receptor assemble as functional homo- and heterodimers (2000) J. Biol. Chem, 275, pp. 7862-7869

Pfeiffer, M., Koch, T., Schroder, H., Klutzny, M., Kirscht, S., Kreienkamp, H.J., Hollt, V., Schulz, S., Homo- and heterodimerization of somatostatin receptor subtypes. Inactivation of sst(3) receptor function by heterodimerization with sst(2A) (2001) J. Biol. Chem, 276, pp. 14027-14036

Rens-Domiano, S., Reisine, T., Biochemical and functional properties of somatostatin receptors (1987) J. Neurochem, 1992, p. 58

Schweitzer, P., Madamba, S., Siggins, G.R., Arachidonic acid metabolites as mediators of somatostatin-induced increase of neuronal M-current (1990) Nature, 346, pp. 464-467

Colas, B., Cambillau, C., Buscail, L., Zeggari, M., Esteve, J.P., Stimulation of a membrane tyrosine phosphatase activity by somatostatin analogues in rat pancreatic acinar cells (1992) Eur. J. Biochem, 207, pp. 1017-1024

Pyronnet, S., Bousquet, C., Najib, S., Azar, R., Laklai, H., Antitumor effects of somatostatin (2008) Mol. Cell. Endocrinol, 286, pp. 230-237

Weckbecker, G., Lewis, I., Albert, R., Schmid, H.A., Hoyer, D., Opportunities in somatostatin research: Biological, chemical and therapeutic aspects (2003) Nat. Rev. Drug Discov, 2, pp. 999-1017

Oberg, K., Neuroendocrine tumors of the gastrointestinal tract: Recent advances in molecular genetics, diagnosis, and treatment (2005) Curr. Opin. Oncol, 17, pp. 386-391

Solcia, E., Kloppel, G., Sobin, H., Histological typing of endocrine tumors (2000) World Health Organization International Histological Classification of Tumors

Volante, M., Rosas, R., Allia, E., Granata, R., Baragli, A., Muccioli, G., Papotti, M., Somatostatin, cortistatin and their receptors in tumours (2008) Mol. Cell Endocrinol, 286, pp. 219-229

Reubi, J.C., Peptide receptors as molecular targets for cancer diagnosis and therapy (2003) Endocrinol. Rev, 24, pp. 389-427

Hofland, L.J., Lamberts, S.W., The pathophysiological consequences of somatostatin receptor internalization and resistance (2003) Endocrinol. Rev, 24, pp. 28-47

de Herder, W.W., Hofland, L.J., van der Lely, A.J., Lamberts, S.W., Somatostatin receptors in gastroentero-pancreatic neuroendocrine tumours (2003) Endocrinol. Relat. Cancer, 10, pp. 451-458

Bauer, W., Briner, U., Doepfner, W., Haller, R., Huguenin, R., SMS 201-995: A very potent and selective octapeptide analogue of somatostatin with prolonged action (1982) Life Sci, 31, pp. 1133-1140

Susini, C., Buscail, L., Rationale for the use of somatostatin analogs as antitumor agents (1733) Ann. Oncol, 2006, p. 17

Bruns, C., Lewis, I., Briner, U., Meno-Tetang, G., Weckbecker, G., SOM230: A novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile (2002) Eur. J. Endocrinol, 146, pp. 707-716

Weckbecker, G., Briner, U., Lewis, I., Bruns, C., SOM230: A new somatostatin peptidomimetic with potent inhibitory effects on the growth hormone/insulin-like growth factor-I axis in rats, primates, and dogs (2002) Endocrinology, 143, pp. 4123-4130

van der Hoek, J., van der Lelij, A.J., Feelders, R.A., de Herder, W.W., Uitterlinden, P., Poon, K.W., Boerlin, V., Lamberts, S.W., The somatostatin analogue SOM230, compared with octreotide, induces differential effects in several metabolic pathways in acromegalic patients (2005) Clin. Endocrinol. (Oxf), 63, pp. 176-184

Schmid, H.A., Development, mechanism of action and potential applications (2008) Mol. Cell Endocrinol, 286, pp. 69-74

Schmid, H.A., Schoeffter, P., Functional activity of the multiligand analog SOM230 at human recombinant somatostatin receptor subtypes supports its usefulness in neuroendocrine tumors (2004) Neuroendocrinology, 80 (SUPPL. 1), pp. 47-50

Valkema, R., De Jong, M., Bakker, W.H., Breeman, W.A., Kooij, P.P., Lugtenburg, P.J., De Jong, F.H., Krenning, E.P., Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: The Rotterdam experience (2002) Semin. Nucl. Med, 32, pp. 110-122

McCarthy, K.E., Woltering, E.A., Anthony, L.B., In situ radiotherapy with 111In-pentetreotide (2000) Q. J. Nucl. Med, 44, pp. 88-95

Anthony, L.B., Woltering, E.A., Espenan, G.D., Cronin, M.D., Maloney, T.J., McCarthy, K.E., Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies (2002) Semin. Nucl. Med, 32, pp. 123-132

Buscombe, J.R., Caplin, M.E., Hilson, A.J., Long-term efficacy of high-activity 111in-pentetreotide therapy in patients with disseminated neuroendocrine tumors (2003) J. Nucl. Med, 44, pp. 1-6

Slooter, G.D., Breeman, W.A., Marquet, R.L., Krenning, E.P., van Eijck, C.H., Anti-proliferative effect of radiolabelled octreotide in a metastases model in rat liver (1999) Int. J. Cancer, 81, pp. 767-771

Reubi, J.C., Schar, J.C., Waser, B., Wenger, S., Heppeler, A., Schmitt, J.S., Macke, H.R., Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use (2000) Eur. J. Nucl. Med, 27, pp. 273-282

Reubi, J. C. DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals. Eur. J. Nucl. Med. Mol. Imaging, 2003, 30, 1338-1347Ginj, M., Chen, J., Walter, M.A., Eltschinger, V., Reubi, J.C., Maecke, H.R., Preclinical evaluation of new and highly potent analogues of octreotide for predictive imaging and targeted radiotherapy (2005) Clin. Cancer Res, 11, pp. 1136-1145

Ginj, M., Schmitt, J.S., Chen, J., Waser, B., Reubi, J.C., de Jong, M., Schulz, S., Maecke, H.R., Design, synthesis, and biological evaluation of somatostatin-based radiopeptides (2006) Chem. Biol, 13, pp. 1081-1090

O'Donoghue, J.A., Bardies, M., Wheldon, T.E., Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides (1902) J. Nucl. Med, 1995, p. 36

de Jong, M., Breeman, W.A., Valkema, R., Bernard, B.F., Krenning, E.P., Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs (2005) J. Nucl. Med, 46 (SUPPL. 1), pp. 13S-17S

Iten, F., Müller, B., Schindler, C., Rochlitz, C., Oertli, D., Mäcke, H.R., Müller-Brand, J., Walter, M.A., Response to [90Yttrium-DOTA]-TOC treatment is associated with long-term survival benefit in metastasized medullary thyroid cancer: A phase II clinical trial (2007) Clin. Cancer Res, 13, pp. 6696-6702

Forrer, F., Valkema, R., Kwekkeboom, D.J., de Jong, M., Krenning, E.P., Neuroendocrine tumors. Peptide receptor radionuclide therapy (2007) Best Pract. Res. Clin. Endocrinol. Metab, 21, pp. 111-129

Forrer, F., Riedweg, I., Maecke, H.R., Mueller-Brand, J., Radiolabeled DOTATOC in patients with advanced paraganglioma and pheochromocytoma (2008) Q. J. Nucl. Med. Mol. Imaging, 52, pp. 334-340

Wehrmann, C., Senftleben, S., Zachert, C., Muller, D., Baum, R.P., Results of individual patient dosimetry in peptide receptor radionuclide therapy with 177Lu DOTA-TATE and 177Lu DOTA-NOC (2007) Cancer Biother. Radiopharm, 22, pp. 406-416

Davi, M.V., Bodei, L., Ferdeghini, M., Falconi, M., Testoni, M., Paganelli, G., Oliani, C., Francia, G., Multidisciplinary approach including receptor radionuclide therapy with 90YDOTATOC ([90Y-DOTA0, Tyr3]-octreotide) and 177Lu DOTATATE ([177Lu-DOTA0, Tyr3]-octreotate) in ectopic cushing syndrome from a metastatic gastrinoma: A promising proposal (2008) Endocr. Pract, 14, pp. 213-218

Raju, M.R., Eisen, Y., Carpenter, S., Inkret, W.C., Radiobiology of alpha particles. III. Cell inactivation by alpha-particle traversals of the cell nucleus (1991) Radiat. Res, 128, pp. 204-209

Geerlings, M. W., Sr.

Geerlings, M. W., Jr.

Scheinberg, D. A. Alphaemitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: Pharmacokinetics, bioactivity, toxicity and chemistry. J. Nucl. Med., 1999, 40, 166-176Miederer, M., Henriksen, G., Alke, A., Mossbrugger, I., Quintanilla-Martinez, L., Senekowitsch-Schmidtke, R., Essler, M., Preclinical Evaluation of the {alpha}-Particle Generator Nuclide 225Ac for Somatostatin Receptor Radiotherapy of Neuroendocrine Tumors (2008) Clin. Cancer Res, 14, pp. 3555-3561

Ginj, M., Zhang, H., Waser, B., Cescato, R., Wild, D., Wang, X., Erchegyi, J., Reubi, J.C., Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors (2006) Proc. Natl. Acad. Sci. USA, 103, pp. 16436-16441

Janson, E.T., Oberg, K., Neuroendocrine tumors - somatostatin receptor expression and somatostatin analog treatment (2003) Cancer Chemother. Biol. Response Modif, 21, pp. 535-546

Gabriel, M., Decristoforo, C., Donnemiller, E., Ulmer, H., Watfah Rychlinski, C., Mather, S.J., Moncayo, R., An intrapatient comparison of 99mTc-EDDA/HYNIC-TOC with 111In-DTPAoctreotide for diagnosis of somatostatin receptor-expressing tumors (2003) J. Nucl. Med, 44, pp. 708-716

Czepczynski, R., Parisella, M.G., Kosowicz, J., Mikolajczak, R., Ziemnicka, K., Gryczynska, M., Sowinski, J., Signore, A., Somatostatin receptor scintigraphy using 99mTc-EDDA/HYNIC-TOC in patients with medullary thyroid carcinoma (2007) Eur. J. Nucl. Med. Mol. Imaging, 34, pp. 1635-1645

Cwikla, J.B., Mikolajczak, R., Pawlak, D., Buscombe, J.R., Nasierowska-Guttmejer, A., Bator, A., Maecke, H.R., Walecki, J., Initial Direct Comparison of 99mTc-TOC and 99mTc-TATE in Identifying Sites of Disease in Patients with Proven GEP NETs (2008) J. Nucl. Med, 49, pp. 1060-1065

Vallabhajosula, S., Moyer, B.R., Lister-James, J., McBride, B.J., Lipszyc, H., Lee, H., Bastidas, D., Dean, R.T., Preclinical evaluation of technetium-99m-labeled somatostatin receptor-binding peptides (1996) J. Nucl. Med, 37, pp. 1016-1022

Menda, Y., Kahn, D., Somatostatin receptor imaging of non-small cell lung cancer with 99mTc depreotide (2002) Semin. Nucl. Med, 32, pp. 92-96

Blum, J., Handmaker, H., Lister-James, J., Rinne, N., A multicenter trial with a somatostatin analog 99mTc depreotide in the evaluation of solitary pulmonary nodules (2000) Chest, 117, pp. 1232-1238

Shah, T., Kulakiene, I., Quigley, A.M., Warbey, V.S., Srirajaskanthan, R., Toumpanakis, C., Hochhauser, D., Caplin, M.E., The role of 99mTc-depreotide in the management of neuroendocrine tumours (2008) Nucl. Med. Commun, 29, pp. 436-440

Antunes, P., Ginj, M., Zhang, H., Waser, B., Baum, R.P., Reubi, J.C., Maecke, H., Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? (2007) Eur. J. Nucl. Med. Mol. Imaging, 34, pp. 982-993

Baum, R., Schmucking, M., Wortmann, R., Muller, M., Zhernosekov, K., Rosch, F., Receptor PET/CT using the Ga-68 labelled somatostatin analog DOTA-1-Nal3-octreotide (DOTA-NOC): Clinical experience in 140 patients (2005) Nuklearmedizin, 44, pp. A57

Hofmann, M., Oei, M., Boerner, A.R., Maecke, H., Geworski, L., Knapp, W.H., Krause, T., Comparison of Ga-68-DOTATOC and Ga-68-DOTANOC for radiopeptide PET (2005) Nuklearmedizin, 44, pp. A58

Win, Z., Rahman, L., Murrell, J., Todd, J., Al-Nahhas, A., The possible role of 68Ga-DOTATATE PET in malignant abdominal paraganglioma (2006) Eur. J. Nucl. Med. Mol. Imaging, 33, p. 506

Traub, T., von Guggenberg, E., Kendler, D., Eisterer, W., Bale, R., Dobrozemsky, G., Gabriel, M., Virgolini, I., First experience with Ga-68-DOTA-lanreotide PET in tumor patients (2005) Nuklearmedizin, 44, pp. A198

Hofmann, M., Maecke, H., Borner, R., Weckesser, E., Schoffski, P., Oei, L., Schumacher, J., Knapp, H., Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: Preliminary data (1751) Eur. J. Nucl. Med, 2001, p. 28

Win, Z., Al-Nahhas, A., Rubello, D., Gross, M.D., Somatostatin receptor PET imaging with Gallium-68 labeled peptides (2007) Q. J. Nucl. Med. Mol. Imaging, 51, pp. 244-250

Meisetschlager, G., Poethko, T., Stahl, A., Wolf, I., Scheidhauer, K., Schottelius, M., Herz, M., Schwaiger, M., (2006) J. Nucl. Med, 47, pp. 566-573

Schottelius, M., Poethko, T., Herz, M., Reubi, J.C., Kessler, H., Schwaiger, M., Wester, H.J., First (18)F-labeled tracer suitable for routine clinical imaging of sst receptor-expressing tumors using positron emission tomography (2004) Clin. Cancer Res, 10, pp. 3593-3606

Folkman, J., Angiogenesis in cancer, vascular, rheumatoid and other disease (1995) Nat. Med, 1, pp. 27-31

Mousa, S.A., Mechamism of angiogensis in vascular disorders: Potential therapeutic targets (1998) Drugs Future, 23, pp. 51-60

Mousa, S.A., Integrins as novel drug discovery targets: Potential therapeutic and diagnostic implications (2000) Emerging Ther. Targets, 4, pp. 389-395

Carmeliet, P., Mechanisms of angiogenesis and arteriogenesis (2000) Nat. Med, 6, pp. 389-395

Bogler, O., Mikkelsen, T., Angiogenesis in glioma: Molecular mechanisms and roadblocks to translation (2003) Cancer J, 9, pp. 205-213

Folkman, J., Role of angiogenesis in tumor growth and metastasis (2002) Semin. Oncol, 29, pp. 15-18

Hwang, R., Varner, J., The role of integrins in tumor angiogenesis (2004) Hematol. Oncol. Clin. North Am, 18, pp. 991-1006. , vii

Ellis, L.M., Liu, W., Fan, F., Jung, Y.D., Reinmuth, N., Stoeltzing, O., Takeda, A., Ahmad, S., Synopsis of angiogenesis inhibitors in oncology (2002) Oncology (Williston Park), 16, pp. 14-22

Jin, H., Varner, J., Integrins: Roles in cancer development and as treatment targets (2004) Br. J. Cancer, 90, pp. 561-565

Kumar, C.C., Integrin alpha v beta 3 as a therapeutic target for blocking tumor-induced angiogenesis (2003) Curr. Drug Targets, 4, pp. 123-131

Brooks, P.C., Clark, R.A., Cheresh, D.A., Requirement of vascular integrin alpha v beta 3 for angiogenesis (1994) Science, 264, pp. 569-571

Ruoslahti, E., Pierschbacher, M.D., New perspectives in cell adhesion: RGD and integrins (1987) Science, 238, pp. 491-497

Ivaska, J., Heino, J., Adhesion receptors and cell invasion: Mechanisms of integrin-guided degradation of extracellular matrix (2000) Cell Mol. Life Sci, 57, pp. 16-24

Hynes, R.O., Integrins: Versatility, modulation, and signaling in cell adhesion (1992) Cell, 69, pp. 11-25

Felding-Habermann, B., O'Toole, T.E., Smith, J.W., Fransvea, E., Ruggeri, Z.M., Ginsberg, M.H., Hughes, P.E., Mueller, B.M., Integrin activation controls metastasis in human breast cancer (1853) Proc. Natl. Acad. Sci. USA, 2001, p. 98

Reinmuth, N., Liu, W., Ahmad, S.A., Fan, F., Stoeltzing, O., Parikh, A.A., Bucana, C.D., Ellis, L.M., Alphavbeta3 integrin antagonist S247 decreases colon cancer metastasis and angiogenesis and improves survival in mice (2003) Cancer Res, 63, pp. 2079-2087

Zhao, Y., Bachelier, R., Treilleux, I., Pujuguet, P., Peyruchaud, O., Baron, R., Clement-Lacroix, P., Clezardin, P., Tumor alphavbeta3 integrin is a therapeutic target for breast cancer bone metastases (2007) Cancer Res, 67, pp. 5821-5830

Eliceiri, B.P., Cheresh, D.A., The role of alphav integrins during angiogenesis: Insights into potential mechanisms of action and clinical development (1999) J. Clin. Invest, 103, pp. 1227-1230

Ruoslahti, E. RGD and other recognition sequences for integrins. Annu. Rev. Cell Dev. Biol., 1996, 12, 697-715Horton, M.A., The alpha v beta 3 integrin "vitronectin receptor (1997) Int. J Biochem. Cell Biol, 29, pp. 721-725

Bello, L., Francolini, M., Marthyn, P., Zhang, J., Carroll, R.S., Nikas, D.C., Strasser, J.F., Black, P.M., Alpha(v)beta3 and alpha(v)beta5 integrin expression in glioma periphery (2001) Neurosurgery, 49, pp. 380-389

Gurrath, M., Muller, G., Kessler, H., Aumailley, M., Timpl, R., Conformation/activity studies of rationally designed potent anti-adhesive RGD peptides (1992) Eur. J. Biochem, 210, pp. 911-921

Pfaff, M., Tangemann, K., Muller, B., Gurrath, M., Muller, G., Selective recognition of cyclic RGD peptides of NMR defined conformation by alpha IIb beta 3, alpha V beta 3, and alpha 5 beta 1 integrins (1994) J. Biol. Chem, 269, pp. 20233-20238

Plow, E.F., Haas, T.A., Zhang, L., Loftus, J., Smith, J.W., Ligand binding to integrins (2000) J. Biol. Chem, 275, pp. 21785-21788

Suehiro, K., Smith, J.W., Plow, E.F., The ligand recognition specificity of beta3 integrins (1996) J. Biol. Chem, 271, pp. 10365-10371

Albelda, S.M., Mette, S.A., Elder, D.E., Stewart, R., Damjanovich, L., Herlyn, M., Buck, C.A., Integrin distribution in malignant melanoma: Association of the beta 3 subunit with tumor progression (1990) Cancer Res, 50, pp. 6757-6764

Falcioni, R., Cimino, L., Gentileschi, M.P., D'Agnano, I., Zupi, G., Kennel, S.J., Sacchi, A., Expression of beta 1, beta 3, beta 4, and beta 5 integrins by human lung carcinoma cells of different histotypes (1994) Exp. Cell Res, 210, pp. 113-122

Meitar, D., Crawford, S.E., Rademaker, A.W., Cohn, S.L., Tumor angiogenesis correlates with metastatic disease, N-myc amplification, and poor outcome in human neuroblastoma (1996) J. Clin. Oncol, 14, pp. 405-414

Gasparini, G., Brooks, P.C., Biganzoli, E., Vermeulen, P.B., Bonoldi, E., Dirix, L.Y., Ranieri, G., Cheresh, D.A., Vascular integrin alpha(v)beta3: A new prognostic indicator in breast cancer (1998) Clin. Cancer Res, 4, pp. 2625-2634

Sengupta, S., Chattopadhyay, N., Mitra, A., Ray, S., Dasgupta, S., Chatterjee, A., Role of alphavbeta3 integrin receptors in breast tumor (2001) J. Exp. Clin. Cancer Res, 20, pp. 585-590

Zitzmann, S., Ehemann, V., Schwab, M., Arginine-glycine-aspartic acid (RGD)-peptide binds to both tumor and tumor-endothelial cells in vivo (2002) Cancer Res, 62, pp. 5139-5143

Weber, W.A., Haubner, R., Vabuliene, E., Kuhnast, B., Wester, H.J., Schwaiger, M., Tumor angiogenesis targeting using imaging agents (2001) Q. J. Nucl. Med, 45, pp. 179-182

Costouros, N.G., Diehn, F.E., Libutti, S.K., Molecular imaging of tumor angiogenesis (2002) J. Cell Biochem. Suppl, 39, pp. 72-78

Van De Wiele, C., Oltenfreiter, R., De Winter, O., Signore, A., Slegers, G., Dierckx, R.A., Tumour angiogenesis pathways: Related clinical issues and implications for nuclear medicine imaging (2002) Eur. J. Nucl. Med. Mol. Imaging, 29, pp. 699-709

Liu, S., Robinson, S.P., Edwards, D.S., Integrin alphaV beta3 directed radiopharmaceutical for tumor imaging (2003) Drugs Future, 28, pp. 551-564

Haubner, R., Wester, H.J., Radiolabeled tracers for imaging of tumor angiogenesis and evaluation of anti-angiogenic therapies (2004) Curr. Pharm. Des, 10, pp. 1439-1455

Chen, X., Multimodality imaging of tumor integrin alphavbeta3 expression (2006) Mini Rev. Med. Chem, 6, pp. 227-234

Haubner, R., Finsinger, D., Kessler, H., Stereoisomeric peptide libraries and peptidomimetics for designing selective inhibitors of the alphaVbeta3 integrin for a new cancer therapy (1997) Angew. Chem. Int. Ed. Engl, 36, pp. 1374-1389

Brooks, P.C., Montgomery, A.M., Rosenfeld, M., Reisfeld, R.A., Hu, T., Klier, G., Cheresh, D.A., Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels (1994) Cell, 79, pp. 1157-1164

Clezardin, P., Recent insights into the role of integrins in cancer metastasis (1998) Cell Mol. Life Sci, 54, pp. 541-548

Aumailley, M., Gurrath, M., Muller, G., Calvete, J., Timpl, R., Arg-Gly-Asp constrained within cyclic pentapeptides. Strong and selective inhibitors of cell adhesion to vitronectin and laminin fragment P1 (1991) FEBS Lett, 291, pp. 50-54

Haubner, R., Gratias, R., Diefenbach, B., Goodman, S.L., Jonczyk, A., Kessler, H.P., Structural and Functional Aspects of RGD-Containing Cyclic Pentapeptides as Highly Potent and Selective Integrin alphaVbeta3 Antagonists (1996) J. Am. Chem. Soc, 118, pp. 7461-7472

Gottschalk, K.E., Kessler, H., The structures of integrins and integrin-ligand complexes: Implications for drug design and signal transduction (2002) Angew. Chem. Int. Ed. Engl, 41, pp. 3767-3774

Bach II, A.C., Espina, J.R., Jackson, S.A., Stouten, P.F.W., Duke, J.L., Mousa, S.A., DeGrado, W.F., Type II' to Type I -Turn Swap Changes Specificity for Integrins (1996) J. Am. Chem. Soc, 118, pp. 293-294

Muller, G., Gurrath, M., Kessler, H., Pharmacophore refinement of gpIIb/ IIIa antagonists based on comparative studies of antiadhesive cyclic and acyclic RGD peptides (1994) J. Comput. Aided Mol. Des, 8, pp. 709-730

Scarborough, R.M., Naughton, M.A., Teng, W., Rose, J.W., Phillips, D.R., Nannizzi, L., Arfsten, A., Charo, I.F., Design of potent and specific integrin antagonists. Peptide antagonists with high specificity for glycoprotein IIb-IIIa (1993) J. Biol. Chem, 268, pp. 1066-1073

Dechantsreiter, M.A., Planker, E., Matha, B., Lohof, E., Holzemann, G., Jonczyk, A., Goodman, S.L., Kessler, H., N-Methylated cyclic RGD peptides as highly active and selective alpha(V)beta(3) integrin antagonists (1999) J. Med. Chem, 42, pp. 3033-3040

Eskens, F.A., Dumez, H., Hoekstra, R., Perschl, A., Brindley, C., Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours (2003) Eur. J. Cancer, 39, pp. 917-926

Haubner, R., Weber, W.A., Beer, A.J., Vabuliene, E., Reim, D., Noninvasive visualization of the activated alphavbeta3 integrin in cancer patients by positron emission tomography and [18F]Galacto-RGD (2005) PLoS Med, 2, pp. e70

Tempia-Caliera, A. A.

Nippgen, J. A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer. BMC Cancer, 2006, 6, 285Beekman, K.W., Colevas, A.D., Cooney, K., Dipaola, R., Dunn, R.L., Gross, M., Keller, E.T., Hussain, M., Phase II evaluations of cilengitide in asymptomatic patients with androgen-independent prostate cancer: Scientific rationale and study design (2006) Clin. Genitourin Cancer, 4, pp. 299-302

Nabors, L.B., Mikkelsen, T., Rosenfeld, S.S., Hochberg, F., Akella, N.S., Fisher, J.D., Cloud, G.A., Grossman, S.A., Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma (2007) J. Clin. Oncol, 25, pp. 1651-1657

Garanger, E., Boturyn, D., Dumy, P., Tumor targeting with RGD peptide ligands-design of new molecular conjugates for imaging and therapy of cancers. Anticancer Agents (2007) Med. Chem, 7, pp. 552-558

MacDonald, T.J., Stewart, C.F., Kocak, M., Goldman, S., Ellenbogen, R.G., Phillips, P., Lafond, D., Kun, L.E., Phase I clinical trial of cilengitide in children with refractory brain tumors: Pediatric Brain Tumor Consortium Study PBTC-012 (2008) J. Clin. Oncol, 26, pp. 919-924

Xiong, J.P., Stehle, T., Diefenbach, B., Zhang, R., Dunker, R., Scott, D.L., Joachimiak, A., Arnaout, M.A., Crystal structure of the extracellular segment of integrin alpha Vbeta3 (2001) Science, 294, pp. 339-345

Thumshirn, G., Hersel, U., Goodman, S.L., Kessler, H., Multimeric cyclic RGD peptides as potential tools for tumor targeting: Solid-phase peptide synthesis and chemoselective oxime ligation (2003) Chemistry, 9, pp. 2717-2725

Wester, H.J., Kessler, H., Molecular targeting with peptides or peptide-polymer conjugates: Just a question of size? (1940) J. Nucl. Med, 2005, p. 46

Boturyn, D., Coll, J.L., Garanger, E., Favrot, M.C., Dumy, P., Template assembled cyclopeptides as multimeric system for integrin targeting and endocytosis (2004) J. Am. Chem. Soc, 126, pp. 5730-5739

Liu, S., Hsieh, W.Y., Kim, Y.S., Mohammed, S.I., Effect of coligands on biodistribution characteristics of ternary ligand 99mTc complexes of a HYNIC-conjugated cyclic RGDfK dimer (2005) Bioconjug. Chem, 16, pp. 1580-1588

de Visser, M., Verwijnen, S.M., de Jong, M., Update: Improvement strategies for peptide receptor scintigraphy and radionuclide therapy (2008) Cancer Biother. Radiopharm, 23, pp. 137-157

Meyer, A., Auernheimer, J., Modlinger, A., Kessler, H., Targeting RGD recognizing integrins: Drug development, biomaterial research, tumor imaging and targeting (2006) Curr. Pharm. Des, 12, pp. 2723-2747

Psimadas, D., Fani, M., Zikos, C., Xanthopoulos, S., Archimandritis, S.C., Varvarigou, A.D., Study of the labeling of two novel RGD-peptidic derivatives with the precursor [99mTc(H2O)3 (CO)3]+ and evaluation for early angiogenesis detection in cancer (2006) Appl. Radiat. Isot, 64, pp. 151-159

Lee, Y.S., Jeong, J.M., Kim, H.W., Chang, Y.S., Kim, Y.J., Hong, M.K., Rai, G.B., Suh, Y.G., An improved method of 18F peptide labeling: Hydrazone formation with HYNIC-conjugated c(RGDyK) (2006) Nucl. Med. Biol, 33, pp. 677-683

Decristoforo, C., Faintuch-Linkowski, B., Rey, A., von Guggenberg, E., Rupprich, M., Hernandez-Gonzales, I., Rodrigo, T., Haubner, R., 99mTc]HYNIC-RGD for imaging integrin alphavbeta3 expression (2006) Nucl. Med. Biol, 33, pp. 945-952

Jia, B., Shi, J., Yang, Z., Xu, B., Liu, Z., Zhao, H., Liu, S., Wang, F., 99mTc-labeled cyclic RGDfK dimer: Initial evaluation for SPECT imaging of glioma integrin alphavbeta3 expression (2006) Bioconjug. Chem, 17, pp. 1069-1076

Liu, S., Edwards, D.S., Ziegler, M.C., Harris, A.R., Hemingway, S.J., Barrett, J.A., 99mTc-labeling of a hydrazinonicotinamide-conjugated vitronectin receptor antagonist useful for imaging tumors (2001) Bioconjug. Chem, 12, pp. 624-629

Mitra, A., Coleman, T., Borgman, M., Nan, A., Ghandehari, H., Line, B.R., Polymeric conjugates of mono- and bi-cyclic alphaVbeta3 binding peptides for tumor targeting (2006) J. Control Rel, 114, pp. 175-183

Dijkgraaf, I., Kruijtzer, J.A., Frielink, C., Soede, A.C., Hilbers, H.W., Oyen, W.J., Corstens, F.H., Boerman, O.C., Synthesis and biological evaluation of potent alphavbeta3-integrin receptor antagonists (2006) Nucl. Med. Biol, 33, pp. 953-961

Dijkgraaf, I., Rijnders, A.Y., Soede, A., Dechesne, A.C., van Esse, G.W., Brouwer, A.J., Corstens, F.H., Liskamp, R.M., Synthesis of DOTA-conjugated multivalent cyclic-RGD peptide dendrimers via 1,3-dipolar cycloaddition and their biological evaluation: Implications for tumor targeting and tumor imaging purposes (2007) Org. Biomol. Chem, 5, pp. 935-944

Dijkgraaf, I., Liu, S., Kruijtzer, J.A., Soede, A.C., Oyen, W.J., Liskamp, R.M., Corstens, F.H., Boerman, O.C., Effects of linker variation on the in vitro and in vivo characteristics of an 111In-labeled RGD peptide (2007) Nucl. Med. Biol, 34, pp. 29-35

Zhang, X., Chen, X., Preparation and characterization of 99mTc(CO)3-BPy-RGD complex as alphav beta3 integrin receptor-targeted imaging agent (2007) Appl. Radiat. Isot, 65, pp. 70-78

Alves, S., Correia, J.D., Gano, L., Rold, T.L., Prasanphanich, A., Haubner, R., Rupprich, M., Smith, C.J., In vitro and in vivo evaluation of a novel 99mTc(CO)3-pyrazolyl conjugate of cyclo-(Arg-Gly-Asp-d-Tyr-Lys) (2007) Bioconjug. Chem, 18, pp. 530-537

Chen, X. microPET of tumor integrin alphavbeta3 expression using 18F-labeled PEGylated tetrameric RGD peptide (18F-FPRGD4). J. Nucl. Med., 2007, 48, 1536-1544Li, Z.B., Wu, Z., Chen, K., Chin, F.T., Chen, X., Click chemistry for (18)F-labeling of RGD peptides and microPET imaging of tumor integrin alphavbeta3 expression (1987) Bioconjug. Chem, 2007, p. 18

Li, Z.B., Cai, W., Cao, Q., Chen, K., Wu, Z., He, L., Chen, X., (64)Cu-labeled tetrameric and octameric RGD peptides for small-animal PET of tumor alpha(v)beta(3) integrin expression (2007) J. Nucl. Med, 48, pp. 1162-1171

Li, Z.B., Chen, K., Chen, X., (68)Ga-labeled multimeric RGD peptides for microPET imaging of integrin alpha(v)beta (3) expression (2008) Eur. J. Nucl. Med. Mol. Imaging, 35, pp. 1100-1108

Edwards, D., Jones, P., Haramis, H., Battle, M., Lear, R., Barnett, D.J., Edwards, C., Godden, V., 99mTc-NC100692 - a tracer for imaging vitronectin receptors associated with angiogenesis: A preclinical investigation (2008) Nucl. Med. Biol, 35, pp. 365-375

Roed, L., Oulie, I., Knuttel, T., Toft, K.G., Hustvedt, S.O., Skotland, T., Metabolism in rats of NC100692, an RGD-peptide for imaging of angiogenesis (2008) J. Pharm. Biomed. Anal, 47, pp. 164-169

Indrevoll, B., Kindberg, G.M., Solbakken, M., Bjurgert, E., Johansen, J.H., Karlsen, H., Mendizabal, M., Cuthbertson, A., NC-100717: A versatile RGD peptide scaffold for angiogenesis imaging (2006) Bioorg. Med.Chem. Lett, 16, pp. 6190-6193

Hua, J., Dobrucki, L.W., Sadeghi, M.M., Zhang, J., Bourke, B.N., Cavaliere, P., Song, J., Sinusas, A.J., Noninvasive imaging of angiogenesis with a 99mTc-labeled peptide targeted at alphavbeta3 integrin after murine hindlimb ischemia (2005) Circulation, 111, pp. 3255-3260

Lindsey, M.L., Escobar, G.P., Dobrucki, L.W., Goshorn, D.K., Bouges, S., Mingoia, J.T., McClister Jr., D.M., Spinale, F.G., Matrix metalloproteinase-9 gene deletion facilitates angiogenesis after myocardial infarction (2006) Am. J. Physiol. Heart Circ. Physiol, 290, pp. H232-H239

Bach-Gansmo, T., Danielsson, R., Saracco, A., Wilczek, B., Bogsrud, T.V., Fangberget, A., Tangerud, A., Tobin, D., Integrin receptor imaging of breast cancer: A proof-of-concept study to evaluate 99mTc-NC100692 (2006) J. Nucl. Med, 47, pp. 1434-1439

Glaser, M., Morrison, M., Solbakken, M., Arukwe, J., Karlsen, H., Wiggen, U., Champion, S., Cuthbertson, A., Radiosynthesis and biodistribution of cyclic RGD peptides conjugated with novel [18F]fluorinated aldehyde-containing prosthetic groups (2008) Bioconjug. Chem, 19, pp. 951-957

Del Gatto, A., Zaccaro, L., Grieco, P., Novellino, E., Zannetti, A., Novel and selective alpha(v)beta3 receptor peptide antagonist: Design, synthesis, and biological behavior (2006) J. Med. Chem, 49, pp. 3416-3420

de Tullio, P., Delarge, J., Pirotte, B., Recent advances in the chemistry of cholecystokinin receptor ligands (agonists and antagonists) (1999) Curr. Med. Chem, 6, pp. 433-455

Escherich, A., Lutz, J., Escrieut, C., Fourmy, D., van Neuren, A.S., Muller, G., Schafferhans, A., Moroder, L., Peptide/ benzodiazepine hybrids as ligands of CCK(A) and CCK(B) receptors (2000) Biopolymers, 56, pp. 55-76

Herranz, R., Cholecystokinin antagonists: Pharmacological and therapeutic potential (2003) Med. Res. Rev, 23, pp. 559-605

Reubi, J.C., Schaer, J.C., Waser, B., Cholecystokinin(CCK)-A and CCK-B/ gastrin receptors in human tumors (1997) Cancer Res, 57, pp. 1377-1386

Berna, M.J., Jensen, R.T., Role of CCK/gastrin receptors in gastrointestinal/metabolic diseases and results of human studies using gastrin/CCK receptor agonists/antagonists in these diseases (2007) Curr. Top. Med. Chem, 7, pp. 1211-1231

Baldwin, G.S., Shulkes, A., CCK receptors and cancer (2007) Curr. Top. Med. Chem, 7, pp. 1232-1238

Reubi, J.C., Targeting CCK receptors in human cancers (2007) Curr. Top. Med. Chem, 7, pp. 1239-1242

Reubi, J.C., Macke, H.R., Krenning, E.P., Candidates for peptide receptor radiotherapy today and in the future (2005) J. Nucl. Med, 46 (SUPPL. 1), pp. 67S-75S

Laverman, P., Behe, M., Oyen, W.J., Willems, P.H., Corstens, F.H., Behr, T.M., Boerman, O.C., Two technetium-99m-labeled cholecystokinin-8 (CCK8) peptides for scintigraphic imaging of CCK receptors (2004) Bioconjug. Chem, 15, pp. 561-568

Wank, S.A., Cholecystokinin receptors (1995) Am. J. Physiol, 269, pp. G628-G646

Mansi, R., Tesauro, D., De Capua, A., Fattorusso, R., Caraco, C., Aloj, L., Benedetti, E., Morelli, G., Peptide-chelating agent conjugate for selective targeting of somatostatin receptor type 1: Synthesis and characterization (2004) Biopolymers, 76, pp. 527-534

Aloj, L., Panico, M., Caraco, C., Del Vecchio, S., Arra, C., Affuso, A., Accardo, A., Salvatore, M., In vitro and in vivo characterization of Indium-111 and Technetium-99m labeled CCK-8 derivatives for CCK-B receptor imaging (2004) Cancer Biother. Radiopharm, 19, pp. 93-98

Aloj, L., Caraco, C., Panico, M., Zannetti, A., Del Vecchio, S., Tesauro, D., De Luca, S., Salvatore, M., In vitro and in vivo evaluation of 111In-DTPAGlu-G-CCK8 for cholecystokinin-B receptor imaging (2004) J. Nucl. Med, 45, pp. 485-494

D'Andrea, L.D., Testa, I., Panico, M., Di Stasi, R., Caraco, C., Tarallo, L., Arra, C., Aloj, L., In vivo and in vitro characterization of CCK8 bearing a histidine-based chelator labeled with (99m)Tc-tricarbonyl (2008) Biopolymers, 90, pp. 707-712

Berna, M.J., Tapia, J.A., Sancho, V., Jensen, R.T., Progress in developing cholecystokinin (CCK)/gastrin receptor ligands that have therapeutic potential (2007) Curr. Opin. Pharmacol, 7, pp. 583-592

De Luca, S., De Capua, A., Saviano, M., Della Moglie, R., Aloj, L., Tarallo, L., Pedone, C., Morelli, G., Synthesis and biological evaluation of cyclic and branched peptide analogues as ligands for cholecystokinin type 1 receptor (2007) Bioorg. Med. Chem, 15, pp. 5845-5853

De Luca, S., Saviano, M., Della Moglie, R., Digilio, G., Bracco, C., Aloj, L., Tarallo, L., Morelli, G., (2006) Chem. Med. Chem, 1, pp. 997-1006

De Luca, S., Morelli, G., Synthesis and characterization of a sulfated and a non-sulfated cyclic CCK8 analogue functionalized with a chelating group for metal labelling (2004) J. Pept. Sci, 10, pp. 265-273

De Luca, S., Ragone, R., Bracco, C., Digilio, G., Aloj, L., Tesauro, D., Saviano, M., Morelli, G., A cyclic CCK8 analogue selective for the cholecystokinin type A receptor: Design, synthesis, NMR structure and binding measurements (2003) Chembiochem, 4, pp. 1176-1187

Morelli, G., De Luca, S., Tesauro, D., Saviano, M., Pedone, C., Dolmella, A., Visentin, R., Mazzi, U., CCK8 peptide derivatized with diphenylphosphine for rhenium labelling: Synthesis and molecular mechanics calculations (2002) J. Pept. Sci, 8, pp. 373-381

Rovati, A.L., Casula, P.L., Da Re, G., Pharmacology and experimental toxicology of a new non-anticholinergic product with antisecretory and gastroprotective activity (CR 242, xylamide-Milid)] (1967) Minerva Med, 58, pp. 3656-3670

Rovati, A.L., Inhibition of gastric secretion by anti-gastrinic and H2-blocking agents (1976) Scand. J. Gastroenterol. Suppl, 42, pp. 113-118

Makovec, F., Bani, M., Cereda, R., Chiste, R., Pacini, M.A., Revel, L., Rovati, L.A., Setnikar, I., Pharmacological properties of lorglumide as a member of a new class of cholecystokinin antagonists (1987) Arzneimittelforschung, 37, pp. 1265-1268

Setnikar, I., Bani, M., Cereda, R., Chiste, R., Makovec, F., Pacini, M.A., Revel, L., Anticholecystokinin activities of loxiglumide (1987) Arzneimittelforschung, 37, pp. 1168-1171

Makovec, F., Peris, W., Revel, L., Giovanetti, R., Mennuni, L., Rovati, L.C., Structure-antigastrin activity relationships of new (R)-4-benzamido-5-oxopentanoic acid derivatives (1992) J. Med. Chem, 35, pp. 28-38

Revel, L., Ferrari, F., Makovec, F., Rovati, L.C., Impicciatore, M., Characterization of antigastrin activity in vivo of CR 2194, a new R-4-benzamido-5-oxo-pentanoic acid derivative (1992) Eur. J. Pharmacol, 216, pp. 217-224

Salerni, B. nhibitory effect of a gastrin receptor antagonist, CR2945, on 1, 2-dimethylhydrazine-induced colorectal cancer in mice. Eur. Surg. Res., 1999, 31, 406-411Giragossian, C., Mierke, D.F., Determination of ligand-receptor interactions of cholecystokinin by nuclear magnetic resonance (2003) Life Sci, 73, pp. 705-713

Okarvi, S. M., Peptide-based radiopharmaceuticals: Future tools for diagnostic imaging of cancers and other diseases (2004) Med. Res. Rev, 24, pp. 357-39

Patel, Y. C., Somatostatin and its receptor family (1999) Front. Neuroendocrinol, 20, pp. 157-198

Lewin, M. J., The somatostatin receptor in the GI tract (1992) Annu. Rev. Physiol, 54, pp. 455-468

Bruno, J. F., Xu, Y., Song, J., Berelowitz, M., Molecular cloning and functional expression of a brain-specific somatostatin receptor (1992) Proc. Natl. Acad. Sci. USA, 89, pp. 11151-11155

Reubi, J. C., Peptide receptors as molecular targets for cancer diagnosis and therapy (2003) Endocrinol. Rev, 24, pp. 389-427

Hofland, L. J., Lamberts, S. W., The pathophysiological consequences of somatostatin receptor internalization and resistance (2003) Endocrinol. Rev, 24, pp. 28-47

de Herder, W. W., Hofland, L. J., van der Lely, A. J., Lamberts, S. W., Somatostatin receptors in gastroentero-pancreatic neuroendocrine tumours (2003) Endocrinol. Relat. Cancer, 10, pp. 451-458

Schmid, H. A., Development, mechanism of action and potential applications (2008) Mol. Cell Endocrinol, 286, pp. 69-74

Schmid, H. A., Schoeffter, P., Functional activity of the multiligand analog SOM230 at human recombinant somatostatin receptor subtypes supports its usefulness in neuroendocrine tumors (2004) Neuroendocrinology, 80 (SUPPL. 1), pp. 47-50

McCarthy, K. E., Woltering, E. A., Anthony, L. B., In situ radiotherapy with 111In-pentetreotide (2000) Q. J. Nucl. Med, 44, pp. 88-95

Anthony, L. B., Woltering, E. A., Espenan, G. D., Cronin, M. D., Maloney, T. J., McCarthy, K. E., Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies (2002) Semin. Nucl. Med, 32, pp. 123-132

Buscombe, J. R., Caplin, M. E., Hilson, A. J., Long-term efficacy of high-activity 111in-pentetreotide therapy in patients with disseminated neuroendocrine tumors (2003) J. Nucl. Med, 44, pp. 1-6

Slooter, G. D., Breeman, W. A., Marquet, R. L., Krenning, E. P., van Eijck, C. H., Anti-proliferative effect of radiolabelled octreotide in a metastases model in rat liver (1999) Int. J. Cancer, 81, pp. 767-771

Reubi, J. C., Schar, J. C., Waser, B., Wenger, S., Heppeler, A., Schmitt, J. S., Macke, H. R., Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use (2000) Eur. J. Nucl. Med, 27, pp. 273-282

O'Donoghue, J. A., Bardies, M., Wheldon, T. E., Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides (1902) J. Nucl. Med, 1995, p. 36

Iten, F., M ller, B., Schindler, C., Rochlitz, C., Oertli, D., M cke, H. R., M ller-Brand, J., Walter, M. A., Response to [90Yttrium-DOTA] -TOC treatment is associated with long-term survival benefit in metastasized medullary thyroid cancer: A phase II clinical trial (2007) Clin. Cancer Res, 13, pp. 6696-6702

Davi, M. V., Bodei, L., Ferdeghini, M., Falconi, M., Testoni, M., Paganelli, G., Oliani, C., Francia, G., Multidisciplinary approach including receptor radionuclide therapy with 90YDOTATOC ([90Y-DOTA0, Tyr3] -octreotide) and 177Lu DOTATATE ([177Lu-DOTA0, Tyr3] -octreotate) in ectopic cushing syndrome from a metastatic gastrinoma: A promising proposal (2008) Endocr. Pract, 14, pp. 213-218

Raju, M. R., Eisen, Y., Carpenter, S., Inkret, W. C., Radiobiology of alpha particles. III. Cell inactivation by alpha-particle traversals of the cell nucleus (1991) Radiat. Res, 128, pp. 204-209

Janson, E. T., Oberg, K., Neuroendocrine tumors - somatostatin receptor expression and somatostatin analog treatment (2003) Cancer Chemother. Biol. Response Modif, 21, pp. 535-546

Cwikla, J. B., Mikolajczak, R., Pawlak, D., Buscombe, J. R., Nasierowska-Guttmejer, A., Bator, A., Maecke, H. R., Walecki, J., Initial Direct Comparison of 99mTc-TOC and 99mTc-TATE in Identifying Sites of Disease in Patients with Proven GEP NETs (2008) J. Nucl. Med, 49, pp. 1060-1065

Mousa, S. A., Mechamism of angiogensis in vascular disorders: Potential therapeutic targets (1998) Drugs Future, 23, pp. 51-60

Mousa, S. A., Integrins as novel drug discovery targets: Potential therapeutic and diagnostic implications (2000) Emerging Ther. Targets, 4, pp. 389-395

Ellis, L. M., Liu, W., Fan, F., Jung, Y. D., Reinmuth, N., Stoeltzing, O., Takeda, A., Ahmad, S., Synopsis of angiogenesis inhibitors in oncology (2002) Oncology (Williston Park), 16, pp. 14-22

Kumar, C. C., Integrin alpha v beta 3 as a therapeutic target for blocking tumor-induced angiogenesis (2003) Curr. Drug Targets, 4, pp. 123-131

Brooks, P. C., Clark, R. A., Cheresh, D. A., Requirement of vascular integrin alpha v beta 3 for angiogenesis (1994) Science, 264, pp. 569-571

Hynes, R. O., Integrins: Versatility, modulation, and signaling in cell adhesion (1992) Cell, 69, pp. 11-25

Eliceiri, B. P., Cheresh, D. A., The role of alphav integrins during angiogenesis: Insights into potential mechanisms of action and clinical development (1999) J. Clin. Invest, 103, pp. 1227-1230

Plow, E. F., Haas, T. A., Zhang, L., Loftus, J., Smith, J. W., Ligand binding to integrins (2000) J. Biol. Chem, 275, pp. 21785-21788

Albelda, S. M., Mette, S. A., Elder, D. E., Stewart, R., Damjanovich, L., Herlyn, M., Buck, C. A., Integrin distribution in malignant melanoma: Association of the beta 3 subunit with tumor progression (1990) Cancer Res, 50, pp. 6757-6764

Weber, W. A., Haubner, R., Vabuliene, E., Kuhnast, B., Wester, H. J., Schwaiger, M., Tumor angiogenesis targeting using imaging agents (2001) Q. J. Nucl. Med, 45, pp. 179-182

Costouros, N. G., Diehn, F. E., Libutti, S. K., Molecular imaging of tumor angiogenesis (2002) J. Cell Biochem. Suppl, 39, pp. 72-78

Brooks, P. C., Montgomery, A. M., Rosenfeld, M., Reisfeld, R. A., Hu, T., Klier, G., Cheresh, D. A., Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels (1994) Cell, 79, pp. 1157-1164

Gottschalk, K. E., Kessler, H., The structures of integrins and integrin-ligand complexes: Implications for drug design and signal transduction (2002) Angew. Chem. Int. Ed. Engl, 41, pp. 3767-3774

Bach II, A. C., Espina, J. R., Jackson, S. A., Stouten, P. F. W., Duke, J. L., Mousa, S. A., DeGrado, W. F., Type II' to Type I -Turn Swap Changes Specificity for Integrins (1996) J. Am. Chem. Soc, 118, pp. 293-294

Scarborough, R. M., Naughton, M. A., Teng, W., Rose, J. W., Phillips, D. R., Nannizzi, L., Arfsten, A., Charo, I. F., Design of potent and specific integrin antagonists. Peptide antagonists with high specificity for glycoprotein IIb-IIIa (1993) J. Biol. Chem, 268, pp. 1066-1073

Dechantsreiter, M. A., Planker, E., Matha, B., Lohof, E., Holzemann, G., Jonczyk, A., Goodman, S. L., Kessler, H., N-Methylated cyclic RGD peptides as highly active and selective alpha (V) beta (3) integrin antagonists (1999) J. Med. Chem, 42, pp. 3033-3040

Eskens, F. A., Dumez, H., Hoekstra, R., Perschl, A., Brindley, C., Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours (2003) Eur. J. Cancer, 39, pp. 917-926

Nabors, L. B., Mikkelsen, T., Rosenfeld, S. S., Hochberg, F., Akella, N. S., Fisher, J. D., Cloud, G. A., Grossman, S. A., Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma (2007) J. Clin. Oncol, 25, pp. 1651-1657

MacDonald, T. J., Stewart, C. F., Kocak, M., Goldman, S., Ellenbogen, R. G., Phillips, P., Lafond, D., Kun, L. E., Phase I clinical trial of cilengitide in children with refractory brain tumors: Pediatric Brain Tumor Consortium Study PBTC-012 (2008) J. Clin. Oncol, 26, pp. 919-924

Xiong, J. P., Stehle, T., Diefenbach, B., Zhang, R., Dunker, R., Scott, D. L., Joachimiak, A., Arnaout, M. A., Crystal structure of the extracellular segment of integrin alpha Vbeta3 (2001) Science, 294, pp. 339-345

Wester, H. J., Kessler, H., Molecular targeting with peptides or peptide-polymer conjugates: Just a question of size? (1940) J. Nucl. Med, 2005, p. 46

Liu, S., Hsieh, W. Y., Kim, Y. S., Mohammed, S. I., Effect of coligands on biodistribution characteristics of ternary ligand 99mTc complexes of a HYNIC-conjugated cyclic RGDfK dimer (2005) Bioconjug. Chem, 16, pp. 1580-1588

Lee, Y. S., Jeong, J. M., Kim, H. W., Chang, Y. S., Kim, Y. J., Hong, M. K., Rai, G. B., Suh, Y. G., An improved method of 18F peptide labeling: Hydrazone formation with HYNIC-conjugated c (RGDyK) (2006) Nucl. Med. Biol, 33, pp. 677-683

Li, Z. B., Cai, W., Cao, Q., Chen, K., Wu, Z., He, L., Chen, X., (64) Cu-labeled tetrameric and octameric RGD peptides for small-animal PET of tumor alpha (v) beta (3) integrin expression (2007) J. Nucl. Med, 48, pp. 1162-1171

Li, Z. B., Chen, K., Chen, X., (68) Ga-labeled multimeric RGD peptides for microPET imaging of integrin alpha (v) beta (3) expression (2008) Eur. J. Nucl. Med. Mol. Imaging, 35, pp. 1100-1108

Lindsey, M. L., Escobar, G. P., Dobrucki, L. W., Goshorn, D. K., Bouges, S., Mingoia, J. T., McClister Jr., D. M., Spinale, F. G., Matrix metalloproteinase-9 gene deletion facilitates angiogenesis after myocardial infarction (2006) Am. J. Physiol. Heart Circ. Physiol, 290, pp. H232-H239

Reubi, J. C., Schaer, J. C., Waser, B., Cholecystokinin (CCK) -A and CCK-B/ gastrin receptors in human tumors (1997) Cancer Res, 57, pp. 1377-1386

Berna, M. J., Jensen, R. T., Role of CCK/gastrin receptors in gastrointestinal/metabolic diseases and results of human studies using gastrin/CCK receptor agonists/antagonists in these diseases (2007) Curr. Top. Med. Chem, 7, pp. 1211-1231

Baldwin, G. S., Shulkes, A., CCK receptors and cancer (2007) Curr. Top. Med. Chem, 7, pp. 1232-1238

Reubi, J. C., Targeting CCK receptors in human cancers (2007) Curr. Top. Med. Chem, 7, pp. 1239-1242

Reubi, J. C., Macke, H. R., Krenning, E. P., Candidates for peptide receptor radiotherapy today and in the future (2005) J. Nucl. Med, 46 (SUPPL. 1), pp. 67S-75S

Wank, S. A., Cholecystokinin receptors (1995) Am. J. Physiol, 269, pp. G628-G646

D'Andrea, L. D., Testa, I., Panico, M., Di Stasi, R., Caraco, C., Tarallo, L., Arra, C., Aloj, L., In vivo and in vitro characterization of CCK8 bearing a histidine-based chelator labeled with (99m) Tc-tricarbonyl (2008) Biopolymers, 90, pp. 707-712

Berna, M. J., Tapia, J. A., Sancho, V., Jensen, R. T., Progress in developing cholecystokinin (CCK) /gastrin receptor ligands that have therapeutic potential (2007) Curr. Opin. Pharmacol, 7, pp. 583-592

Rovati, A. L., Casula, P. L., Da Re, G., Pharmacology and experimental toxicology of a new non-anticholinergic product with antisecretory and gastroprotective activity (CR 242, xylamide-Milid)] (1967) Minerva Med, 58, pp. 3656-3670

Rovati, A. L., Inhibition of gastric secretion by anti-gastrinic and H2-blocking agents (1976) Scand. J. Gastroenterol. Suppl, 42, pp. 113-118



The use of peptides as targeting tools has been validated in different applications. In particular radiolabelled peptides with adequate stability, receptor-binding properties and biokinetic behaviour have been investigated as an important class of radiopharmaceuticals for cancer pathology imaging and therapy. This review focuses on recent progress in design and synthetic modifications of small biologically active peptides used in diagnosis and therapy. In particular, we report the current development and optimization of suitable peptides for targeting three relevant biological receptors (CCK, somatostatin, and integrin receptors) involved in specific tumour diseases.
    Targeted Drug Delivery by integrin avb3 antagonist

Contiene: [X]      Estesa     Autori: [X]  Tipo di lavoro: [X]   Data iniziale: Data finale: [X]      Sede: Affiliazione IBB     
    
[Pulisci modulo]


Hill BS, Sarnella A, Capasso D, Comegna D, Del Gatto A, Gramanzini M, Albanese S, Saviano M, Zaccaro L, Zannetti A
* Therapeutic Potential of a Novel alphavbeta(3) Antagonist to Hamper the Aggressiveness of Mesenchymal Triple Negative Breast Cancer Sub-Type (3 visite) (PDF 2 visite)
N/D (ISSN: 2072-6694linking), 2019 Jan 24; 11(2): N/D-N/D.
Impact Factor: 5.326
Dettagli    Esporta in BibTeX    Esporta in EndNote

Bolzati C, Salvarese N, Carpanese D, Seraglia R, Melendez-alafort L, Rosato A, Capasso D, Saviano M, Del Gatto A, Comegna D, Zaccaro L
* [(99m)Tc][Tc(N)PNP43]-Labeled RGD Peptides As New Probes for a Selective Detection of alphavbeta3 Integrin: Synthesis, Structure-Activity and Pharmacokinetic Studies (19 visite)
J Med Chem (ISSN: 0022-2623linking, 0022-2623print, 1520-4804electronic), 2018 Nov 8; 61(21): 9596-9610.
Impact Factor: 6.253
Dettagli    Esporta in BibTeX    Esporta in EndNote

Monti M, De Rosa V, Iommelli F, Carriero MV, Terlizzi C, Camerlingo R, Belli S, Fonti R, Di Minno G, Del Vecchio S
* Neutrophil Extracellular Traps as an Adhesion Substrate for Different Tumor Cells Expressing RGD-Binding Integrins (24 visite)
Int J Mol Sc (ISSN: 1422-0067linking, 1422-0067electronic, 1661-6596), 2018 Aug 9; 19(8): N/D-N/D.
Impact Factor: 3.687
Dettagli    Esporta in BibTeX    Esporta in EndNote

Comegna D, Zannetti A, Del Gatto A, De Paola I, Russo L, Di Gaetano S, Liguoro A, Capasso D, Saviano M, Zaccaro L
* Chemical Modification for Proteolytic Stabilization of the Selective alphavbeta3 Integrin RGDechi Peptide: in Vitro and in Vivo Activities on Malignant Melanoma Cells (332 visite) (PDF 81 visite)
J Med Chem (ISSN: 1520-4804electronic, 0022-2623linking, 0022-2623print), 2017 Dec 14; 60(23): 9874-9884.
Impact Factor: 5.207
Dettagli    Esporta in BibTeX    Esporta in EndNote

Depalo N, Corricelli M, De Paola I, Valente G, Iacobazzi RM, Altamura E, Debellis D, Comegna D, Fanizza E, Denora N, Laquintana V, Mavelli F, Striccoli M, Saviano M, Agostiano A, Del Gatto A, Zaccaro L, Curri ML
* NIR Emitting Nanoprobes Based on Cyclic RGD Motif Conjugated PbS Quantum Dots for Integrin-Targeted Optical Bioimaging (53 visite) (PDF 60 visite)
Acs Appl Mater Interfaces (ISSN: 1944-8252electronic, 1944-8244linking), 2017 Dec 13; 9(49): 43113-43126.
Impact Factor: 7.504
Dettagli    Esporta in BibTeX    Esporta in EndNote

Camorani S, Crescenzi E, Gramanzini M, Fedele M, Zannetti A, Cerchia L
* Aptamer-mediated impairment of EGFR-integrin alphavbeta3 complex inhibits vasculogenic mimicry and growth of triple-negative breast cancers (71 visite) (PDF 105 visite)
Sci Rep (ISSN: 2045-2322electronic, 2045-2322linking), 2017 Apr 20; 7: 46659-46659.
Impact Factor: 4.259
Dettagli    Esporta in BibTeX    Esporta in EndNote

Monti M, Iommelli F, De Rosa V, Carriero MV, Miceli R, Camerlingo R, Di Minno G, Del Vecchio S
* Integrin-dependent cell adhesion to neutrophil extracellular traps through engagement of fibronectin in neutrophil-like cells (95 visite)
Plosone (ISSN: 1932-6203, 1932-6203electronic), 2017 Feb; 12(2): 1-15.
Impact Factor: 3.54
Dettagli    Esporta in BibTeX    Esporta in EndNote

Pisani A, Sabbatini M, Imbriaco M, Riccio E, Rubis N, Prinster A, Perna A, Liuzzi R, Spinelli L, Santangelo M, Remuzzi G, Ruggenenti P
* Long-term Effects of Octreotide on Liver Volume in Patients With Polycystic Kidney and Liver Disease (84 visite)
Clin Gastroenterol Hepatol (ISSN: 1542-7714electronic, 1542-3565linking), 2016 Feb 1; N/D: N/D-N/D.
Impact Factor: 7.398
Dettagli    Esporta in BibTeX    Esporta in EndNote

Farina B, De Paola I, Russo L, Capasso D, Liguoro A, Gatto AD, Saviano M, Pedone PV, Di Gaetano S, Malgieri G, Zaccaro L, Fattorusso R
* A Combined NMR and Computational Approach to Determine the RGDechi-hCit-alphav beta3 Integrin Recognition Mode in Isolated Cell Membranes (100 visite)
Chemistry (ISSN: 1521-3765electronic, 0947-6539linking), 2016 Jan 11; 22(2): 681-693.
Impact Factor: 5.317
Dettagli    Esporta in BibTeX    Esporta in EndNote

Di Pietro P, Zaccaro L, Comegna D, Del Gatto A, Saviano M, Snyders R, Cossement D, Satriano C, Rizzarelli E
* Silver nanoparticles functionalized with a fluorescent cyclic RGD peptide: a versatile integrin targeting platform for cells and bacteria (57 visite) (PDF 53 visite)
The Royal Society Of Chemistry, 2016 Jan 01; 6: N/D-N/D.
Impact Factor: 3.564
Dettagli    Esporta in BibTeX    Esporta in EndNote

Valente G, Depalo N, De Paola I, Iacobazzi RM, Denora N, Laquintana V, Comparelli R, Altamura E, Latronico T, Altomare M, Fanizza E, Striccoli M, Agostiano A, Saviano M, Del Gatto A, Zaccaro L, Curri ML
* Integrin-targeting with peptide-bioconjugated semiconductor-magnetic nanocrystalline heterostructures (119 visite)
Nano Research (ISSN: 1998-0124), 2016; 9(3): 644-662.
Impact Factor: 7.354
Dettagli    Esporta in BibTeX    Esporta in EndNote

Merlino F, Brancaccio D, Yousif AM, Piras L, Campiglia P, Gomez-monterrey I, Santicioli P, Meini S, Maggi CA, Novellino E, Carotenuto A, Grieco P
* Structure-Activity Study of the Peptides P5U and Urantide by the Development of Analogues Containing Uncoded Amino Acids at Position9 (118 visite)
Chemmedchem (ISSN: 1860-7179, 1860-7187, 1860-7187electronic), 2016; N/D: N/D-N/D.
Impact Factor: 3.225
Dettagli    Esporta in BibTeX    Esporta in EndNote

Calvanese L, Falcigno L, D'Auria G
* Essential Dynamics Analysis Captures the Concerted Motion of the Integrin-Binding Site in Jerdostatin, an RTS Disintegrin (126 visite)
Biopolymers (ISSN: 0006-3525, 0006-6352, 0006-3525print), 2015 Mar; 103(3): 158-166.
Impact Factor: 2.248
Dettagli    Esporta in BibTeX    Esporta in EndNote

Nardon C, Boscutti G, Dalla Via L, Ringhieri P, Di Noto V, Morelli G, Accardo A, Fregona D
* CCK8 peptide-labeled Pluronic® F127 micelles as a targeted vehicle of gold-based anticancer chemotherapeutics (148 visite)
Medchemcomm Royal Society Of Chemistry (ISSN: 2040-2503), 2015; 6(1): 155-163.
Impact Factor: 2.319
Dettagli    Esporta in BibTeX    Esporta in EndNote

Camera L, Severino R, Faggiano A, Masone S, Mansueto G, Maurea S, Fonti R, Salvatore M
* Contrast enhanced multi-detector CT and MR findings of a well-differentiated pancreatic vipoma (127 visite)
World J Radiol (ISSN: 1949-8470, 1949-8470electronic, 1949-8470linking), 2014 Oct 28; 6(10): 840-845.
Impact Factor: 0.567
Dettagli    Esporta in BibTeX    Esporta in EndNote

Ramundo V, Del Prete M, Marotta V, Marciello F, Camera L, Napolitano V,  de LucaL, Circelli L, Colantuoni V, Di Sarno A, Carratu AC, Di Roseto CDL, Colao A, Faggiano A
* Impact of long-acting octreotide in patients with early-stage MEN1-related duodeno-pancreatic neuroendocrine tumours (160 visite)
Clin Endocrinol (ISSN: 0300-0664, 1365-2265, 1365-2265electronic), 2014 Jun; 80(6): 850-855.
Impact Factor: 3.457
Dettagli    Esporta in BibTeX    Esporta in EndNote

Accardo A, Aloj L, Aurilio M, Morelli G, Tesauro D
* Receptor binding peptides for target-selective delivery of nanoparticles encapsulated drugs (199 visite)
Int J Nanomed (ISSN: 1176-9114, 1178-2013, 1178-2013electronic), 2014 Mar 27; 9(1): 1537-1557.
Impact Factor: 4.383
Dettagli    Esporta in BibTeX    Esporta in EndNote

Nold-Petry CA, Rudloff I, Baumer Y, Ruvo M, Marasco D, Botti P, Farkas L, Cho SX, Zepp JA, Azam T, Dinkel H, Palmer BE, Boisvert WA, Cool CD, Taraseviciene-Stewart L, Heinhuis B, Joosten LA, Dinarello CA, Voelkel NF, Nold MF
* IL-32 Promotes Angiogenesis (197 visite)
Journal Of Immunology (ISSN: 0022-1767), 2014 Jan 15; 192(2): 589-602.
Impact Factor: 4.922
Dettagli    Esporta in BibTeX    Esporta in EndNote

Dynkevich Y, Rother KI, Whitford I, Qureshi S, Galiveeti S, Szulc AL, Danoff A, Breen TL, Kaviani N, Shanik MH, LeRoith D, Vigneri R, Koch CA, Roth J
* Tumors, IGF-2, and Hypoglycemia: Insights From the Clinic, the Laboratory, and the Historical Archive (690 visite)
Endocrine Reviews (ISSN: 0163-769x), 2013 Dec; 34(6): 798-826.
Impact Factor: 19.358
Dettagli    Esporta in BibTeX    Esporta in EndNote

Accardo A, Mangiapia G, Paduano L, Morelli G, Tesauro D
* Octreotide labeled aggregates containing platinum complexes as nanovectors for drug delivery (159 visite)
J Pept Sci (ISSN: 1075-2617, 1099-1387, 1075-2617print), 2013 Apr; 19(4): 190-197.
Impact Factor: 1.862
Dettagli    Esporta in BibTeX    Esporta in EndNote

Pisano M, De Paola I, Nieddu V, Sassu I, Cossu S, Galleri G, Del Gatto A, Budroni M, Cossu A, Saviano M, Palmieri G, Zaccaro L, Rozzo C
* In vitro activity of the alphavbeta3 integrin antagonist RGDechi-hCit on malignant melanoma cells (111 visite)
Anticancer Res (ISSN: 0250-7005, 0250-0700, 1791-7530electronic), 2013 Mar; 33(3): 871-879.
Impact Factor: 1.045
Dettagli    Esporta in BibTeX    Esporta in EndNote

Berisio R
* Learning from pathogens: Exploiting host-pathogen liaison for therapeutic development (127 visite)
Curr Protein Pept Sci (ISSN: 1389-2037), 2012 Dec; 13(8): 697-698.
Impact Factor: 2.326
Dettagli    Esporta in BibTeX    Esporta in EndNote

Magrì A, D'Alessandro F, Di Stefano DA, Campagna T, Pappalardo G, Impellizzeri G, La Mendola D
* Copper(ii) Coordination Properties Of The Integrin Ligand Sequence Phsrn And Its New Beta-Cyclodextrin Conjugates (160 visite)
Journal Of Inorganic Biochemistry, 2012 Sep; 113: 15-24.
Impact Factor: 3.444
Dettagli    Esporta in BibTeX    Esporta in EndNote

D'Agata R, Spoto G
* Artificial DNA and surface plasmon resonance (198 visite)
Artificial Dna Pna & Xna (ISSN: 1949-095x), 2012 Apr; 3(2): N/D-N/D.
Impact Factor: 0
Dettagli    Esporta in BibTeX    Esporta in EndNote

Scarí G, Porta F, Fascio U, Avvakumova S, Dal Santo V, De Simone M, Saviano M, Leone M, Del Gatto A, Pedone C, Zaccaro L
* Gold nanoparticles capped by a GC-containing peptide functionalized with an RGD motif for integrin targeting (157 visite)
Bioconjug Chem (ISSN: 1520-4812, 1043-1802, 1520-4812electronic), 2012 Mar 21; 23(3): 340-349.
Impact Factor: 4.58
Dettagli    Esporta in BibTeX    Esporta in EndNote

Faggiano A, Ramundo V, Del Prete M, Marotta V, Marciello F, Camera L, Napolitano V,  de LucaL, Lombardi G, Colao A
* Long-Acting Somatostatin Analogues are Highly Effective in Patients with Early Stage MEN-1-Related Well-Differentiated Neuroendocrine Tumors (82 visite)
Neuroendocrinology (ISSN: 0028-3835), 2012; 96: N/D-N/D.
Impact Factor: 3.537
Dettagli    Esporta in BibTeX    Esporta in EndNote

Ocak M, Helbok A, Rangger C, Peitl PK, Nock BA, Morelli G, Eek A, Sosabowskijk, Breeman WA, Reubi JC, Decristoforo C
* Comparison of biological stability and metabolism of CCK2 receptor targeting peptides, a collaborative project under COST BM0607 (176 visite)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2011 Sep; 38(8): 1426-1435.
Impact Factor: 4.991
Dettagli    Esporta in BibTeX    Esporta in EndNote

Zaccaro L, Garcia-lopez Mt Gonzalez-muniz RG
* TRPV1 modulators: Structure-activity relationships using a rational combinatorial approach (102 visite)
Bioorganic & Medicinal Chemistry Letters (ISSN: 0960-894x), 2011 Jun 15; 21(12): 3541-3545.
Impact Factor: 2.554
Dettagli    Esporta in BibTeX    Esporta in EndNote

Tornesello AL, Aurilio M, Accardo A, Tarallo L, Barbieri A, Arra C, Tesauro D, Morelli G, Aloj L
* Gastrin and cholecystokinin peptide-based radiopharmaceuticals: An in vivo and in vitro comparison (138 visite)
J Pept Sci (ISSN: 1075-2617, 1099-1387, 1075-2617print), 2011 May; 17(5): 405-412.
Impact Factor: 1.799
Dettagli    Esporta in BibTeX    Esporta in EndNote

Perrone-filardi P, Dellegrottaglie S, Rudd JH, Costanzo P, Marciano C, Vassallo E, Marsico F, Ruggiero D, Petretta MP, Chiariello M, Cuocolo A
* Molecular imaging of atherosclerosis in translational medicine (183 visite)
Eur J Nucl Med (ISSN: 1619-7089, 1619-7070, 0340-6997), 2011 May; 38(5): 969-975.
Impact Factor: 4.991
Dettagli    Esporta in BibTeX    Esporta in EndNote

Accardo A, Morisco A, Palladino P, Palumbo R, Tesauro D, Morelli G
* Amphiphilic CCK peptides assembled in supramolecular aggregates: Structural investigations and in vitro studies (161 visite)
Mol Biosyst (ISSN: 1742-206x), 2011 Mar; 7(3): 862-870.
Impact Factor: 3.534
Dettagli    Esporta in BibTeX    Esporta in EndNote

Accardo A, Morisco A, Gianolio E, Tesauro D, Mangiapia G, Radulescu A, Brandt A, Morelli G
* Nanoparticles containing octreotide peptides and gadolinium complexes for MRI applications (186 visite)
J Pept Sci (ISSN: 1075-2617, 1099-1387, 1075-2617print), 2011 Feb; 17(2): 154-162.
Impact Factor: 1.799
Dettagli    Esporta in BibTeX    Esporta in EndNote

Accardo A, Morisco A, Tesauro D, Pedone C, Morelli G
* Naposomes: A new class of peptide-derivatized, target-selective multimodal nanoparticles for imaging and therapeutic applications (181 visite)
Ther Deliv (ISSN: 2041-5990), 2011 Feb; 2(2): 235-257.
Impact Factor: 0
Dettagli    Esporta in BibTeX    Esporta in EndNote

Santulli G, Basilicata MF, De Simone M, Del Giudice C, Anastasio A, Sorriento D, Saviano M, Del Gatto A, Trimarco B, Pedone C, Zaccaro L, Iaccarino G
* Evaluation of the anti-angiogenic properties of the new selective alphaVbeta3 integrin antagonist RGDechiHCit (120 visite)
J Transl Med Journal Of Translational Medicine (ISSN: 1479-5876electronic), 2011 Jan 13; 9: 7-7.
Impact Factor: 3.474
Dettagli    Esporta in BibTeX    Esporta in EndNote

Morisco A, Accardo A, Tesauro D, Palumbo R, Benedetti E, Morelli G
* Peptide-labeled supramolecular aggregates as selective doxorubicin carriers for delivery to tumor cells (115 visite)
Biopolymers (ISSN: 0006-3525, 0006-6352, 0006-3525print), 2011; 96(1): 88-96.
Impact Factor: 2.87
Dettagli    Esporta in BibTeX    Esporta in EndNote

Guarnieri D, De Capua A, Ventre M, Borzacchiello A, Pedone C, Marasco D, Ruvo M, Netti PA
* Covalently immobilized RGD gradient on PEG hydrogel scaffold influences cell migration parameters (119 visite)
Acta Biomaterialia (ISSN: 1878-7568, 1742-7061), 2010 Jul; 6(7): 2532-2539.
Impact Factor: 4.824
Dettagli    Esporta in BibTeX    Esporta in EndNote

Bombardieri E, Ambrosini V, Aktolun C, Baum RP, Bishof-delaloye A, Del Vecchio S, Maffioli L, Mortelmans L, Oyen W, Pepe G, Chiti A
* In-111-pentetreotide scintigraphy: procedure guidelines for tumour imaging (165 visite)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2010 Jul; 37(7): 1441-1448.
Impact Factor: 5.036
Dettagli    Esporta in BibTeX    Esporta in EndNote

Monfregola L, Saviano M, De Luca S
* Synthesis and Characterization of a Selective Alpha(v)Beta(3) Receptor Cyclic Peptide Antagonist Functionalized with a Chelating Group for Metal Labelling (101 visite)
Int J Pept Res Ther (ISSN: 1573-3149, 0929-5666), 2010 Mar; 16(1): 1-5.
Impact Factor: 1.034
Dettagli    Esporta in BibTeX    Esporta in EndNote

Satriano C, Messina GM, Marino C, Aiello I, Conte E, La Mendola D, Distefano DA, D'Alessandro F, Pappalardo G, Impellizzeri G
* Surface immobilization of fibronectin-derived PHSRN peptide on functionalized polymer films - Effects on fibroblast spreading (168 visite)
J Colloid Interface Sci (ISSN: 1095-7103electronic, 0021-9797linking), 2010 Jan 15; 341(2): 232-239.
Impact Factor: 3.068
Dettagli    Esporta in BibTeX    Esporta in EndNote

Zannetti A, Del Vecchio S, Iommelli F, Del Gatto A,  De Luca S, Zaccaro L, Papaccioli A, Sommella J, Panico M, Speranza A, Grieco P, Novellino E, Saviano M, Pedone C, Salvatore M
* Imaging of alpha(v)beta(3) expression by a bifunctional chimeric RGD peptide not cross-reacting with alpha(v)beta(5) (113 visite)
Clin Cancer Res (ISSN: 1078-0432, 1078-0432linking, 1078-0432print), 2009 Sep 15; 15(16): 5224-5233.
Impact Factor: 6.747
Dettagli    Esporta in BibTeX    Esporta in EndNote

Zannetti A, Del Vecchio S, Iommelli F, Del Gatto A, De Luca S, Zaccaro L, Papaccioli A, Sommella J, Panico M, Speranza A, Grieco P, Novellino E, Saviano M, Pedone C, Salvatore M
* Imaging of αvβ3 expression by a bifunctional chimeric RGD peptide not cross-reacting with α vβ5 (147 visite)
Clin Cancer Res (ISSN: 1078-0432, 1078-0432linking, 1078-0432print), 2009 Sep 15; 15(16): 5224-5233.
Impact Factor: 6.747
Dettagli    Esporta in BibTeX    Esporta in EndNote

Accardo A, Tesauro D, Morisco A, Mangiapia G, Vaccaro M, Gianolio E, Heenan RK, Paduano L, Morelli G
* Micelles obtained by aggregation of gemini surfactants containing the CCK8 peptide and a gadolinium complex (157 visite)
J Biol Inorg Chem (ISSN: 0949-8257, 1432-1327electronic, 0949-8257linking), 2009 May; 14(4): 587-599.
Impact Factor: 3.415
Dettagli    Esporta in BibTeX    Esporta in EndNote

Ciaccio C, Tundo GR, Grasso G, Spoto G, Marasco D, Ruvo M, Gioia M, Rizzarelli E, Coletta M
* Somatostatin: a novel substrate and a modulator of insulin-degrading enzyme activity (135 visite)
J Mol Biol (ISSN: 1089-8638, 0022-2836, 1089-8638electronic), 2009 Feb 6; 385(5): 1556-1567.
Impact Factor: 3.871
Dettagli    Esporta in BibTeX    Esporta in EndNote

De Luca S, Del Gatto A, Ruvo M, Panico M, Zannetti A, Del Vecchio S, Salvatore M, Pedone C, Saviano M, Zaccaro L
* A new and selective radiolabeled alpha(V)beta(3) peptide antagonist as tracer in tumor diagnosis (101 visite)
Adv Exp Med Biol (ISSN: 0065-2598, 0065-2598print), 2009; 611: 439-440.
Impact Factor: 2.02
Dettagli    Esporta in BibTeX    Esporta in EndNote

Accardo A, Tesauro D, Morelli G, Del Pozzo L, Pedone C, Tornesello AL, Benedetti E
* Supramolecular aggregates derivatized by CCK8 peptide as selective nanocarriers for drug delivery (97 visite)
Adv Exp Med Biol (ISSN: 0065-2598, 0065-2598print), 2009; 611: 603-604.
Impact Factor: 2.02
Dettagli    Esporta in BibTeX    Esporta in EndNote

Vaccaro M, Mangiapia G, Accardo A, Tesauro D, Gianolio E, Frielinghaus H, Morelli G, Paduano L
* Polymerized mixed aggregates containing gadolinium complex and CCK8 peptide (103 visite)
Colloid Polym Sci (ISSN: 0303-402x), 2008 Dec; 286(14-15): 1643-1652.
Impact Factor: 1.736
Dettagli    Esporta in BibTeX    Esporta in EndNote

Storto G, Erra P, Pellegrino T, Nardelli A, Milone F, Di Giorgio E, Faggiano A, Castaldi E, Ortosecco G, Speranza A, Klain M, Colao A, Salvatore M, Pace L
* Efficacy and Toxicity of Peptide Receptor Radionuclide Therapy (PRRT) using medium-high activities of Y-90-DOTA-Octreotate (Y-90-DOTATATE) in patients with tumours expressing somatostatin receptors (SSTR) (102 visite)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2008 Oct; 35: N/D-N/D.
Impact Factor: 4.532
Dettagli    Esporta in BibTeX    Esporta in EndNote

Accardo A, Tesauro D, Del Pozzo L, Mangiapia G, Paduano L, Morelli G
* Micelles by self-assembling peptide-conjugate amphiphile: Synthesis and structural characterization (149 visite)
J Pept Sci (ISSN: 1075-2617, 1099-1387, 1075-2617print), 2008 Sep; 14(8): 903-910.
Impact Factor: 1.654
Dettagli    Esporta in BibTeX    Esporta in EndNote

Accardo A, Tesauro D, Aloj L, Tarallo L, Arra C, Mangiapia G, Vaccaro M, Pedone C, Paduano L, Morelli G
* Peptide-containing aggregates as selective nanocarriers for therapeutics (111 visite)
Chemmedchem (ISSN: 1860-7179, 1860-7187, 1860-7187electronic), 2008 Apr; 3(4): 594-602.
Impact Factor: 3.15
Dettagli    Esporta in BibTeX    Esporta in EndNote

Pulcrano M, Camera L, Pagano L, Del Vecchio S, Ferone D, Bodei L, Murgia A, Pace L, Storto G, Paganelli G, Colao A, Salvatore M, Lombardi G, Biondi B
* Usefulness of [(111)In-DTPA(0)] octreotide scintigraphy in a family with von Hippel-Lindau disease (165 visite)
J Endocrinol Invest (ISSN: 0391-4097, 1720-8386electronic), 2008 Apr; 31(4): 352-359.
Impact Factor: 1.888
Dettagli    Esporta in BibTeX    Esporta in EndNote

Leese MP, Jourdan FL, Gaukroger K, Mahon MF, Newman SP, Foster PA, Stengel C, Regis-Lydi S, Ferrandis E, Di Fiore A, De Simone G, Supuran CT, Purohit A, Reed MJ, Potter BVL
* Structure-activity relationships of C-17 cyano-substituted estratrienes as anticancer agents (130 visite)
J Med Chem (ISSN: 0022-2623, 1520-4804, 0022-2623print), 2008 Mar 13; 51(5): 1295-1308.
Impact Factor: 4.898
Dettagli    Esporta in BibTeX    Esporta in EndNote

Saviano M, De Luca S, Morelli G, Tesauro D, Pedone C
* Preparation and use of cyclic and branched peptides and their labelled derivatives as therapeutic agents, cholecystokinin agonists or antagonists, and diagnostic agents to identify and locate tumours (131 visite)
Patents Official Gazette Of The United States Patent And Trademark Office (ISSN: 0098-1133), 2008 Feb 12; N/D: N/D-N/D.
Impact Factor: 0
Dettagli    Esporta in BibTeX    Esporta in EndNote

D'Andrea LD, Testa I, Panico M, Di Stasi R, Carac C, Tarallo L, Arra C, Barbieri A, Romanelli A, Aloj L
* In vivo and in vitro characterization of CCK8 bearing a histidine-based chelator labeled with Tc-99m-tricarbonyl (188 visite)
Biopolymers (ISSN: 0006-3525, 0006-6352, 0006-3525print), 2008; 90(5): 707-712.
Impact Factor: 2.823
Dettagli    Esporta in BibTeX    Esporta in EndNote

Del Vecchio S, Zannetti A, Panico M, Speranza A, Iommelli F, Papaccioli A, Sommella J, Lettieri A, Saviano M, Zaccaro L, Del Gatto A, Lang L, Pedone C, Salvatore M
* In vivo imaging of alpha(v) beta(3) integrin expression with a radiolabeled chimeric RGD peptide (107 visite)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2007 Oct; 34: N/D-N/D.
Impact Factor: 4.101
Dettagli    Esporta in BibTeX    Esporta in EndNote

De Luca S, De Capua A, Saviano M, Della Moglie R, Aloj L, Tarallo L, Pedone C, Morelli G
* Synthesis and biological evaluation of cyclic and branched peptide analogues as ligands for cholecystokinin type 1 receptor (110 visite)
Bioorg Med Chem (ISSN: 0968-0896, 1464-3391, 1464-3391electronic), 2007 Sep 1; 15(17): 5845-5853.
Impact Factor: 2.662
Dettagli    Esporta in BibTeX    Esporta in EndNote

Vaccaro M, Accardo A, D'Errico G, Schillen K, Radulescu A, Tesauro D, Morelli G, Paduano L
* Peptides and gd complexes containing colloidal assemblies as tumor-specific contrast agents in MRI: Physicochemical characterization (128 visite)
Biophysical Journal (ISSN: 0006-3495, 1542-0086), 2007 Sep; 93(5): 1736-1746.
Impact Factor: 4.627
Dettagli    Esporta in BibTeX    Esporta in EndNote

Tesauro D, Accardo A, Gianolio E, Paduano L, Teixeira J, Schillén K, Aime S, Morelli G
* Peptide derivatized lamellar aggregates as target-specific MRI contrast agents (145 visite)
Chembiochem (ISSN: 1439-4227, 1439-7633, 1439-7633electronic), 2007 May 25; 8(8): 950-955.
Impact Factor: 3.446
Dettagli    Esporta in BibTeX    Esporta in EndNote

Agostini S, Bolzati C, Didonè E, Cavazza-Ceccato M, Refosco F, Aloj L, Arra C, Aurilio M, Tornesello AL, Tesauro D, Morelli G
* The (Tc(N)(PNP))2+ metal fragment labeled cholecystokinin-8 (CCK8) peptide for CCK-2 receptors imaging: In vitro and in vivo studies (148 visite)
J Pept Sci (ISSN: 1075-2617, 1099-1387, 1075-2617print), 2007 Apr; 13(4): 211-219.
Impact Factor: 1.768
Dettagli    Esporta in BibTeX    Esporta in EndNote

Accardo A, Tesauro D, Morelli G, Gianolio E, Aime S, Vaccaro M, Mangiapia G, Paduano L, Schillén K
* High-relaxivity supramolecular aggregates containing peptides and Gd complexes as contrast agents in MRI (140 visite)
J Biol Inorg Chem (ISSN: 0949-8257, 1432-1327electronic, 0949-8257print), 2007 Feb; 12(2): 267-276.
Impact Factor: 3.325
Dettagli    Esporta in BibTeX    Esporta in EndNote

Zaccaro L, Del Gatto A, Pedone C, Saviano M
* Integrin Receptor Family: Promising Target For Therapeutic And Diagnostic Applications (100 visite)
Current Topics In Biochemical Research (ISSN: 0972-4583), 2007; 9(2): 45-56.
Impact Factor: 0
Dettagli    Esporta in BibTeX    Esporta in EndNote

Benedetti E, Pedone C, Saviano M
* Structure-activity relationships in peptides: From modelling to rational drug design (140 visite)
Front Drug Des And Discov (ISSN: 1574-0889), 2007; 3(1): 539-558.
Impact Factor: 0
Dettagli    Esporta in BibTeX    Esporta in EndNote

Aloj L, Aurilio M, Rinaldi V, D'Ambrosio L, Tesauro D, Peitl PK, Maina T, Mansi R, Von Guggenberg E, Joosten L, Sosabowski JK, Breeman WA, De Blois E, Koelewijn S, Melis M, Waser B, Beetschen K, Reubi JC, De Jong M
* The EEE project (111 visite)
Proc Int Cosm Ray Conf Icrc Universidad Nacional Autonoma De Mexico, 2007; 5(HEPART2): 977-980.
Impact Factor: 0
Dettagli    Esporta in BibTeX    Esporta in EndNote

De Luca S, Saviano M, Della Moglie R, Digilio G, Bracco C, Aloj L, Tarallo L, Pedone C, Morelli G
* Conformationally constrained CCK8 analogues obtained from a rationally designed peptide library as ligands for cholecystokinin type B receptor (115 visite)
Chemmedchem (ISSN: 1860-7179, 1860-7187, 1860-7187electronic), 2006 Sep; 1(9): 997-1006.
Impact Factor: 3.046
Dettagli    Esporta in BibTeX    Esporta in EndNote

Del Gatto A, Zaccaro L, Grieco P, Novellino E, Zannetti A, Del Vecchio S, Iommelli F, Salvatore M, Pedone C, Saviano M
* Novel And Selective Alpha (v) Beta3 Receptor Peptide Antagonist: Design, Synthesis, And Biological Behavior (173 visite)
J Med Chem (ISSN: 0022-2623, 1520-4804, 0022-2623print), 2006 Jun 1; 49(11): 3416-3420.
Impact Factor: 5.115
Dettagli    Esporta in BibTeX    Esporta in EndNote

De Luca S, Saviano M, Lassiani L, Yannakopoulou K, Stefanidou P, Aloj L, Morelli G, Varnavas A
* Anthranilic acid based CCK1 receptor antagonists and CCK-8 have a common step in their "receptor desmodynamic processes" (148 visite)
J Med Chem (ISSN: 0022-2623, 1520-4804, 0022-2623print), 2006 Apr 20; 49(8): 2456-2462.
Impact Factor: 5.115
Dettagli    Esporta in BibTeX    Esporta in EndNote

D'Andrea LD, Del Gatto A, Pedone C, Benedetti E
* Peptide-based molecules in angiogenesis (154 visite)
Chem Biol Drug Des Chemical Biology And Drug Design (ISSN: 1747-0277, 1747-0285), 2006 Feb; 67(2): 115-126.
Impact Factor: 2.507
Dettagli    Esporta in BibTeX    Esporta in EndNote

Del Vecchio S, Zannetti A, Del Gatto A, Grieco P, Iommelli F, Zaccaro L, Panico M, Saviano M, Blystone SD, Pedone C, Salvatore M
* Characterization of a novel RGD-containing peptide with improved selectivity for imaging alpha v beta 3 integrin expression (118 visite)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2005 Sep; 32: N/D-N/D.
Impact Factor: 3.883
Dettagli    Esporta in BibTeX    Esporta in EndNote

De Luca S, Sanseverino M, Zocchi I, Pedone C, Morelli G, Ragone R
* Receptor fragment approach to the binding between CCK8 peptide and cholecystokinin receptors: A fluorescence study on type B receptor fragment CCKB-R (352-379) (106 visite)
Biopolymers (ISSN: 0006-3525, 0006-6352, 0006-3525print), 2005 Mar; 77(4): 205-211.
Impact Factor: 2.545
Dettagli    Esporta in BibTeX    Esporta in EndNote

Vitale RM, Pedone C, De Benedetti PG, Fanelli F
* Structural features of the inactive and active states of the melanin-concentrating hormone receptors: Insights from molecular simulations (179 visite)
Proteins (ISSN: 0887-3585, 1097-0134, 1097-0134electronic), 2004 Sep 15; 56(3): 430-448.
Impact Factor: 4.429
Dettagli    Esporta in BibTeX    Esporta in EndNote

De Luca S, Morelli G
* Synthesis and characterization of a sulfated and a non-sulfated cyclic CCK8 analogue functionalized with a chelating group for metal labelling (99 visite)
J Pept Sci (ISSN: 1075-2617, 1099-1387, 1075-2617print), 2004 May; 10(5): 265-273.
Impact Factor: 1.652
Dettagli    Esporta in BibTeX    Esporta in EndNote

Accardo A, Tesauro D, Roscigno P, Gianolio E, Paduano L, D'Errico G, Pedone C, Morelli G
* Physicochemical Properties of Mixed Micellar Aggregates Containing CCK Peptides and Gd Complexes Designed as Tumor Specific Contrast Agents in MRI (138 visite)
J Am Chem Soc (ISSN: 0002-7863, 0002-2786, 1520-5126), 2004 Mar 17; 126(10): 3097-3107.
Impact Factor: 6.903
Dettagli    Esporta in BibTeX    Esporta in EndNote

Aloj L, Caracò C, Panico M, Zannetti A, Del Vecchio S, Tesauro D, De Luca S, Arra C, Pedone C, Morelli G, Salvatore M
* In vitro and in vivo evaluation of In-111-DTPAGlu-G-CCK8 for cholecystokinin-B receptor imaging (169 visite)
J Nucl Med (ISSN: 1535-5667, 0161-5505, 1535-5667electronic), 2004 Mar; 45(3): 485-494.
Impact Factor: 5.362
Dettagli    Esporta in BibTeX    Esporta in EndNote

Aloj L, Panico M, Caraco C, Del Vecchio S, Arra C, Affuso A, Accardo A, Mansi R, Tesauro D, De Luca S, Pedone C, Visentin R, Mazzi U, Morelli G, Salvatore M
* In vitro and in vivo characterization of Indium-111 and Technetium-99m labeled CCK-8 derivatives for CCK-B receptor imaging (114 visite)
Cancer Biotherapy And Radiopharmaceuticals (ISSN: 1084-9785, 1084-4978), 2004 Feb; 19(1): 93-98.
Impact Factor: 1.091
Dettagli    Esporta in BibTeX    Esporta in EndNote

Mansi R, Tesauro D, De Capua A, Fattorusso R, Carac C, Aloj L, Benedetti E, Morelli G
* Peptide-chelating agent conjugate for selective targeting of somatostatin receptor type 1: Synthesis and characterization (127 visite)
Biopolymers (ISSN: 0006-3525, 0006-6352, 0006-3525print), 2004; 76(6): 527-534.
Impact Factor: 2.863
Dettagli    Esporta in BibTeX    Esporta in EndNote

De Luca S, Ragone R, Bracco C, Digilio G, Aloj L, Tesauro D, Saviano M, Pedone C, Morelli G
* A cyclic CCK8 analogue selective for the cholecystokinin type A receptor: design, synthesis, NMR structure and binding measurements (128 visite)
Chembiochem (ISSN: 1439-7633, 1439-4227, 1439-7633electronic), 2003 Nov 7; 4(11): 1176-1187.
Impact Factor: 3.992
Dettagli    Esporta in BibTeX    Esporta in EndNote

De Luca S, Ragone R, Bracco C, Digilio G, Tesauro D, Saviano M, Pedone C, Morelli G
* The role of segment 32-47 of cholecystokinin receptor type A in CCK8 binding: Synthesis, nuclear magnetic resonance, circular dichroism and fluorescence studies (108 visite)
J Pept Sci (ISSN: 1075-2617, 1099-1387, 1075-2617print), 2003 Mar; 9(3): 156-169.
Impact Factor: 1.377
Dettagli    Esporta in BibTeX    Esporta in EndNote

Colao A, Marzullo P, Cuocolo A, Spinelli L, Pivonello R, Bonaduce D, Salvatore M, Lombardi G
* Reversal of acromegalic cardiomyopathy in young but not in middle-aged patients after 12 months of treatment with the depot long-acting somatostatin analogue octreotide (124 visite)
Clin Endocrinol (ISSN: 0300-0664, 1365-2265, 1365-2265electronic), 2003 Feb; 58(2): 169-176.
Impact Factor: 2.767
Dettagli    Esporta in BibTeX    Esporta in EndNote

Camera L, Del Vecchio S, Quarantelli M, Ibello F, Pellegrino T, Salvatore M
* Radiolabeled somatostatin analogs in the diagnosis and staging of neuroendocrine tumors (103 visite)
J Endocrinol Invest (ISSN: 0391-4097, 1720-8386electronic), 2003; 26(8Suppl): 60-62.
Impact Factor: 1.621
Dettagli    Esporta in BibTeX    Esporta in EndNote

Morelli G, De Luca S, Tesauro D, Saviano M, Pedone C, Dolmella A, Visentin R, Mazzi U
* CCK8 peptide derivatized with diphenylphosphine for rhenium labelling: Synthesis and molecular mechanics calculations (100 visite)
J Pept Sci (ISSN: 1075-2617, 1099-1387, 1075-2617print), 2002 Jul; 8(7): 373-381.
Impact Factor: 1.691
Dettagli    Esporta in BibTeX    Esporta in EndNote

Aloj L, Panico M, Caracó C, Zannetti A, Del Vecchio S, Di Nuzzo C, Arra C, Morelli G, Tesauro D, De Luca S, Pedone C, Salvatore M
* Radiolabeling approaches for cholecystokinin B receptor imaging (147 visite)
Biopolymers (ISSN: 0006-3525, 0006-6352, 0006-3525print), 2002; 66(6): 370-380.
Impact Factor: 2.372
Dettagli    Esporta in BibTeX    Esporta in EndNote

De Luca S, Tesauro D, Di Lello P, Fattorusso R, Saviano M, Pedone C, Morelli G
* Synthesis and solution characterization of a porphyrin-CCK8 conjugate (117 visite)
J Pept Sci (ISSN: 1075-2617, 1099-1387, 1075-2617print), 2001 Jul; 7(7): 386-394.
Impact Factor: 1.451
Dettagli    Esporta in BibTeX    Esporta in EndNote

Colao A, Marzullo P, Ferone D, Spinelli L, Cuocolo A, Bonaduce D, Salvatore M, Boerlin V, Lancranjan I, Lombardi G
Cardiovascular effects of depot long-acting somatostatin analog sandostatin LAR in acromegaly (121 visite)
J Clin Endocrinol Metab (ISSN: 0021-972x), 2000 Sep; 85(9): 3132-3140.
Impact Factor: 5.447
Dettagli    Esporta in BibTeX    Esporta in EndNote

Ragone R, De Luca S, Tesauro D, Pedone C, Morelli G
Fluorescence studies on the binding between 1-47 fragment of cholecystokinin receptor CCKA-R(1-47) and nonsulfated cholecystokinin octapeptide CCK8 (123 visite)
Biopolymers (ISSN: 0006-3525, 0006-6352, 0006-3525print), 2000; 56(1): 47-53.
Impact Factor: 2.405
Dettagli    Esporta in BibTeX    Esporta in EndNote

Colao A, Lastoria S, Ferone D, Varrella P, Marzullo P, Pivonello R, Cerbone G, Acampa W, Salvatore M, Lombardi G
The pituitary uptake of In-111-DTPA-D-Phe(1)-octreotide in the normal pituitary and in pituitary adenomas (116 visite)
J Endocrinol Invest (ISSN: 0391-4097, 1720-8386electronic), 1999 Mar; 22(3): 176-183.
Impact Factor: 0.957
Dettagli    Esporta in BibTeX    Esporta in EndNote

Lastoria S, Vergara E, Palmieri G, Acampa W, Varrella P, Caracò C, Bianco RA, Muto P, Salvatore M
In vivo detection of malignant thymic masses by indium-111-DTPA-D- Phe1-octreotide scintigraphy (110 visite)
J Nucl Med (ISSN: 0161-5505, 1535-5667, 1535-5667electronic), 1998 Apr; 39(4): 634-639.
Impact Factor: 3.064
Dettagli    Esporta in BibTeX    Esporta in EndNote

Maurea S, Lastoria S, Caracò C, Klain M, Varrella P, Acampa W, Muto P, Salvatore M
The role of radiolabeled somatostatin analogs in adrenal imaging (108 visite)
Nucl Med Biol (ISSN: 0969-8051, 0883-2897), 1996 Sep; 23(6): 677-680.
Impact Factor: 1.042
Dettagli    Esporta in BibTeX    Esporta in EndNote

Lastoria S, Muto P, Acampa W, Caraco C, Vergara E, Varrella P, Pezzullo L, Ionna F, Mozzillo N, ListerJames J, Salvatore M
Somatostatin receptor scintigraphy (SRS) with technetium-99m labeled synthetic peptides in melanoma (107 visite)
J Nucl Med (ISSN: 0161-5505, 1535-5667, 1535-5667electronic), 1996 May; 37(5SUPPL.): N/D-N/D.
Impact Factor: 3.491
Dettagli    Esporta in BibTeX    Esporta in EndNote

Lastoria S, Maurea S, Vergara E, Acampa W, Varrella P, Klain M, Muto P, Bernardy JD, Salvatore M
Comparison of labeled MIBG and somatostatin analogs in imaging neuroendocrine tumors (112 visite)
Q J Nucl Med (ISSN: 1125-0135, 1124-3937), 1995 Dec; 39(4Suppl1): 145-149.
Impact Factor: 2.125
Dettagli    Esporta in BibTeX    Esporta in EndNote

Muto P, Lastoria S, Vergara E, Caraco C, Varrella P, Bernardy JD, Acampa W, Salvatore M
Tc-99m labeled somatostatin analogs to image tumors expressing specific receptors (83 visite)
J Nucl Med (ISSN: 0161-5505, 1535-5667, 1535-5667electronic), 1995; 36(5SUPPL.): N/D-N/D.
Impact Factor: 3.491
Dettagli    Esporta in BibTeX    Esporta in EndNote

LASTORIA S, VERGARA E, VARRELLA P, ACAMPA W, PALMIERI G, SALVATORE M
IN-VIVO DETECTION OF NEW DISEASES EXPRESSING SOMATOSTATIN RECEPTORS BY IN-111 OCTREOTIDE (82 visite)
J Nucl Med (ISSN: 0161-5505, 1535-5667, 1535-5667electronic), 1994 May; 35(5): N/D-N/D.
Impact Factor: 3.491
Dettagli    Esporta in BibTeX    Esporta in EndNote

LASTORIA S, VERGARA E, VARRELLA P, ACAMPA W, PALMIERI G, SALVATORE M
IN-VIVO DETECTION OF NEW NEOPLASTIC LESIONS EXPRESSING SOMATOSTATIN RECEPTORS USING IN-111 OCTREOTIDE (99 visite)
Posters Tomes 1 4proceedings Of The Xvi International Cancer Congress Free Papers And, 1994; N/D: N/D-N/D.
Impact Factor: 0
Dettagli    Esporta in BibTeX    Esporta in EndNote



91 Records (82 escludendo Abstract e Conferenze).
Impact factor totale: 307.381 (280.855 escludendo Abstract e Conferenze).
Impact factor a 5 anni totale: 309.72 (276.763 escludendo Abstract e Conferenze).







    Esporta in BibTeX    Esporta in EndNote

Ultima modifica di Marco Comerci in data Thursday 19 March 2015, 14:43:18
216 visite. Ultima visita in data Sunday 30 December 2018, 3:28:14

Webmaster and developer: Marco Comerci
Per problemi e suggerimenti: adminibb.cnr.it
Ultimo aggiornamento: Wednesday 20 February 2019, 11:48:26